PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10721683-1 2000 OBJECTIVE: To investigate the effect of amitriptyline, bupropion, doxepin or venlafaxine on the gene expression of the neuroprotective enzyme superoxide dismutase (SOD1) in a catecholamine cell in vitro model. Bupropion 55-64 superoxide dismutase 1 Rattus norvegicus 164-168 10721683-7 2000 The addition of bupropion, doxepin or venlafaxine to PC12 cell cultures also up-regulated SOD1 mRNA. Bupropion 16-25 superoxide dismutase 1 Rattus norvegicus 90-94 10404470-2 1999 Herein, imidazoline receptor binding protein (IRBP) antiserum was used to quantify imidazoline receptors on platelets of depressed patients before and after treatment with the atypical aminoketone antidepressant, bupropion. Bupropion 213-222 growth factor receptor bound protein 10 Homo sapiens 8-44 10404470-2 1999 Herein, imidazoline receptor binding protein (IRBP) antiserum was used to quantify imidazoline receptors on platelets of depressed patients before and after treatment with the atypical aminoketone antidepressant, bupropion. Bupropion 213-222 growth factor receptor bound protein 10 Homo sapiens 46-50 10404470-5 1999 Following 6 weeks" treatment with bupropion, IRBP-immunodensity was downregulated in depressed patients (p = 0.03, paired t-test); predominantly in responders (p = 0.005). Bupropion 34-43 growth factor receptor bound protein 10 Homo sapiens 45-49 10404470-7 1999 IRBP-immunodensity was negatively correlated (r = -0.79, p = 0.01) with plasma concentrations of bupropion and its metabolites at week-4 of BUP treatment. Bupropion 97-106 growth factor receptor bound protein 10 Homo sapiens 0-4 10404470-8 1999 Thus, a 33-kDa IRBP on platelet plasma membranes is elevated in depression and normalized in responders to bupropion. Bupropion 107-116 growth factor receptor bound protein 10 Homo sapiens 15-19 9862757-2 1999 The present study establishes the acute functional effects of bupropion, phencyclidine, and ibogaine on two human nAChR subtypes. Bupropion 62-71 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 114-119 9723124-0 1998 Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Bupropion 0-9 solute carrier family 6 member 3 Rattus norvegicus 35-55 9541153-15 1998 CONCLUSION: Bupropion administration may be a safe and effective method of treating SRI-induced sexual dysfunction. Bupropion 12-21 sorcin Homo sapiens 84-87 8885123-7 1996 The potential accumulation of hydroxybupropion after CYP2D6 inhibition may, however, contribute to toxicity and impair bupropion"s therapeutic effectiveness. Bupropion 37-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 53-59 8842333-0 1996 Different effects of the antidepressant drugs imipramine, maprotiline and bupropion on insulin secretion from mouse pancreatic islets. Bupropion 74-83 insulin Oryctolagus cuniculus 87-94 8842333-3 1996 Maprotiline and bupropion stimulated insulin release, while imipramine was without any effect in presence of 8.3 mmol/l glucose. Bupropion 16-25 insulin Oryctolagus cuniculus 37-44 8842333-5 1996 Bupropion inversely significantly stimulated the insulin secretion in presence of 16.7 mmol/l glucose. Bupropion 0-9 insulin Oryctolagus cuniculus 49-56 7717410-3 1995 The response of ADHD patients to medications that inhibit the dopamine transporter, including methylphenidate, amphetamine, pemoline, and bupropion, led us to consider the dopamine transporter as a primary candidate gene for ADHD. Bupropion 138-147 solute carrier family 6 member 3 Homo sapiens 62-82 7717410-3 1995 The response of ADHD patients to medications that inhibit the dopamine transporter, including methylphenidate, amphetamine, pemoline, and bupropion, led us to consider the dopamine transporter as a primary candidate gene for ADHD. Bupropion 138-147 solute carrier family 6 member 3 Homo sapiens 172-192 7807588-13 1994 3) By preventing translocation of the DA transporter mobile moiety, nomifensine may inhibit the release of DA induced by external DA or bupropion and by drastic drops in the external Cl- concentration. Bupropion 136-145 solute carrier family 6 member 3 Rattus norvegicus 38-52 8240925-1 1993 The synthesis of the enantiomers of bupropion, (rac)-2-tert-butylamino-3"-chloropropiophenone 1 (Wellbutrin) is described. Bupropion 36-45 thymoma viral proto-oncogene 1 Mus musculus 48-51 8240925-1 1993 The synthesis of the enantiomers of bupropion, (rac)-2-tert-butylamino-3"-chloropropiophenone 1 (Wellbutrin) is described. Bupropion 97-107 thymoma viral proto-oncogene 1 Mus musculus 48-51 1541607-0 1992 Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD. Bupropion 15-24 glutamate decarboxylase 1 Homo sapiens 81-84 1347953-6 1992 It is concluded that bupropion-induced hypothermia may be mediated through D-2 receptor activation, while the reversal of reserpine-induced hypothermia by bupropion may be exerted through beta-adrenergic stimulation. Bupropion 21-30 dopamine receptor D2 Mus musculus 75-87 33811859-9 2021 Furthermore, a partial antagonist of alpha7-nAChR, bupropion, rescued IL-6 but not GRO-alpha or I-309 production. Bupropion 51-60 interleukin 6 Homo sapiens 70-74 33806634-0 2021 Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network. Bupropion 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 85-91 33806634-1 2021 The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug-drug interaction (DDI) studies. Bupropion 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 78-84 33806634-1 2021 The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug-drug interaction (DDI) studies. Bupropion 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 157-163 33806634-4 2021 It incorporates CYP2B6-mediated hydroxylation of bupropion, metabolism via CYP2C19 and 11beta-HSD, as well as binding to pharmacological targets. Bupropion 49-58 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 33236485-0 2021 Weight Loss Response to Naltrexone/Bupropion is Modulated by the Taq1A Genetic Variant near DRD2 (rs1800497): A Pilot Study. Bupropion 35-44 dopamine receptor D2 Homo sapiens 92-96 34910929-5 2022 In terms of mode of reversible inhibition, vicagrel exhibited mixed-type inhibition of CYP2B6-catalyzed bupropion hydroxylation and noncompetitive inhibition of CYP2C19-mediated S-mephenytoin 4"-hydroxylation with Ki values of 0.19 muM and 1.2 muM, respectively. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-93 34752647-0 2022 Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis. Bupropion 49-58 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 34752647-1 2022 INTRODUCTION: Bupropion is metabolized to its active metabolite, hydroxybupropion (HB), by the genetically polymorphic cytochrome P450 2B6 (CYP2B6) enzyme. Bupropion 14-23 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-138 34752647-1 2022 INTRODUCTION: Bupropion is metabolized to its active metabolite, hydroxybupropion (HB), by the genetically polymorphic cytochrome P450 2B6 (CYP2B6) enzyme. Bupropion 14-23 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 140-146 34752647-3 2022 OBJECTIVES: A systematic review and meta-analysis was conducted to quantify the association of bupropion and HB exposure with CYP2B6 variant alleles and genotype-defined metabolizer phenotypes. Bupropion 95-104 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 126-132 34752647-6 2022 The ratio of means (RoM) between CYP2B6 genotype or genotype-defined phenotype groups for bupropion exposure was calculated for each study and combined in a meta-analysis. Bupropion 90-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 33-39 34752647-9 2022 The AUCs of HB and the active moiety (bupropion + HB) were significantly reduced in CYP2B6*6 carriers compared to the non-carriers (HB: RoM 0.77, 95% CI 0.71-0.83; active moiety: RoM 0.81, 95% CI 0.75-0.88). Bupropion 38-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 84-90 34752647-12 2022 The findings of this study suggest opportunities to further study precision dosing strategies for bupropion therapy based on CYP2B6 genotype. Bupropion 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 125-131 34936033-3 2021 Here we identify hippocampal bone morphogenetic protein (BMP) signaling as a common downstream pathway that mediates the behavioral effects of five different antidepressant classes (fluoxetine, bupropion, duloxetine, vilazodone, trazodone) and of electroconvulsive therapy. Bupropion 194-203 bone morphogenetic protein 1 Homo sapiens 29-55 34936033-3 2021 Here we identify hippocampal bone morphogenetic protein (BMP) signaling as a common downstream pathway that mediates the behavioral effects of five different antidepressant classes (fluoxetine, bupropion, duloxetine, vilazodone, trazodone) and of electroconvulsive therapy. Bupropion 194-203 bone morphogenetic protein 1 Homo sapiens 57-60 34877801-1 2022 This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics (PK) of cytochrome P450 probes (bupropion, CYP2B6; midazolam, CYP3A4/5; warfarin, CYP2C9; omeprazole, CYP2C19) in healthy subjects. Bupropion 165-174 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 141-156 34498115-0 2021 Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns. Bupropion 22-31 protein phosphatase 1, regulatory inhibitor subunit 1B Mus musculus 122-130 34791718-2 2022 BACKGROUND AND AIMS: CYP2B6, a genetically variable enzyme, converts bupropion to its active metabolite hydroxybupropion. Bupropion 69-78 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 34791718-4 2022 The aim of this study was to determine whether genetically normal (vs. reduced) CYP2B6 activity increases bupropion-aided cessation in African American smokers via higher hydroxybupropion concentration, and whether this differs by sex. Bupropion 106-115 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-86 34791718-13 2022 CONCLUSIONS: In African American light-smokers with verified early bupropion use, genetically normal CYP2B6 activity appears to be indirectly associated with greater smoking cessation success in a relationship mediated by higher hydroxybupropion concentration. Bupropion 67-76 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 34218389-0 2021 Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3. Bupropion 11-20 toll like receptor 2 Homo sapiens 66-70 34218389-0 2021 Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3. Bupropion 11-20 toll like receptor 4 Homo sapiens 71-75 34218389-0 2021 Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3. Bupropion 11-20 Janus kinase 2 Homo sapiens 80-84 34218389-0 2021 Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3. Bupropion 11-20 signal transducer and activator of transcription 3 Homo sapiens 85-90 34218389-9 2021 Bupropion reduced IL-17A, TNFalpha, and IL-1beta protein levels in the cultures. Bupropion 0-9 interleukin 17A Homo sapiens 18-24 34218389-9 2021 Bupropion reduced IL-17A, TNFalpha, and IL-1beta protein levels in the cultures. Bupropion 0-9 tumor necrosis factor Homo sapiens 26-34 34218389-9 2021 Bupropion reduced IL-17A, TNFalpha, and IL-1beta protein levels in the cultures. Bupropion 0-9 interleukin 1 alpha Homo sapiens 40-48 34218389-10 2021 Nonetheless, bupropion increased IL-1beta (P < 0.0001), TNFalpha (P < 0.0001), and IL-17A (P < 0.05) mRNA levels. Bupropion 13-22 interleukin 1 alpha Homo sapiens 33-41 34218389-10 2021 Nonetheless, bupropion increased IL-1beta (P < 0.0001), TNFalpha (P < 0.0001), and IL-17A (P < 0.05) mRNA levels. Bupropion 13-22 tumor necrosis factor Homo sapiens 56-64 34218389-10 2021 Nonetheless, bupropion increased IL-1beta (P < 0.0001), TNFalpha (P < 0.0001), and IL-17A (P < 0.05) mRNA levels. Bupropion 13-22 interleukin 17A Homo sapiens 83-89 34218389-12 2021 TLR2 (P < 0.0001), TLR4 (P < 0.0001), JAK2 (P < 0.0001), and STAT3 (P < 0.0001) gene expression also rose in response to bupropion. Bupropion 121-130 toll like receptor 2 Homo sapiens 0-4 34218389-12 2021 TLR2 (P < 0.0001), TLR4 (P < 0.0001), JAK2 (P < 0.0001), and STAT3 (P < 0.0001) gene expression also rose in response to bupropion. Bupropion 121-130 toll like receptor 4 Homo sapiens 19-23 34218389-12 2021 TLR2 (P < 0.0001), TLR4 (P < 0.0001), JAK2 (P < 0.0001), and STAT3 (P < 0.0001) gene expression also rose in response to bupropion. Bupropion 121-130 Janus kinase 2 Homo sapiens 38-42 34218389-12 2021 TLR2 (P < 0.0001), TLR4 (P < 0.0001), JAK2 (P < 0.0001), and STAT3 (P < 0.0001) gene expression also rose in response to bupropion. Bupropion 121-130 signal transducer and activator of transcription 3 Homo sapiens 61-66 34305134-0 2021 A 19-Year-Old Woman with a History of Depression and Fatal Cardiorespiratory Failure Following an Overdose of Prescribed Bupropion. Bupropion 121-130 immunoglobulin kappa variable 2-28 Homo sapiens 0-4 34305134-2 2021 This report is of a case of a 19-year-old woman with a history of depression who suffered fatal cardiorespiratory failure following an overdose of prescribed bupropion. Bupropion 158-167 immunoglobulin kappa variable 2-28 Homo sapiens 28-32 34305134-3 2021 CASE REPORT A 19-year-old woman presented to the Emergency Department with an estimated bupropion overdose of 28.2 g and possible oxcarbazepine co-ingestion. Bupropion 88-97 immunoglobulin kappa variable 2-28 Homo sapiens 12-16 35614973-7 2022 Previous work has identified two DAT pharmacological chaperones with moderate potency and efficacy: bupropion and ibogaine. Bupropion 100-109 solute carrier family 6 member 3 Homo sapiens 33-36 35512805-1 2022 Striking stereoselective disposition of the antidepressant and smoking cessation aid bupropion and its active metabolites observed clinically influence patients" response to BUP therapy and its clinically important drug-drug interactions (DDI) with CYP2D6 substrates. Bupropion 85-94 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 249-255 35194103-1 2022 Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone). Bupropion 217-226 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 6-12 35194103-1 2022 Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone). Bupropion 217-226 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 85-100 34985532-11 2022 CONCLUSIONS: Together, these studies demonstrate that METH-induced neurotoxicity impairs dopamine D1 receptor-dependent LTP within the DMS and that the FDA-approved drug bupropion restores induction of striatal LTP in mice with METH-induced dopamine neurotoxicity. Bupropion 170-179 dopamine receptor D1 Mus musculus 89-109 2506597-5 1989 Bupropion, in contrast, had a modest effect only in CD-1 mice. Bupropion 0-9 CD1 antigen complex Mus musculus 52-56 3149241-1 1988 Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion 15-24 C-C motif chemokine ligand 4 Rattus norvegicus 93-97 3114793-0 1987 The effect of bupropion on prolactin in a patient with a pituitary microadenoma. Bupropion 14-23 prolactin Homo sapiens 27-36 6312356-5 1983 Bupropion neither inhibits MAO (monoamine oxidase) nor releases biogenic amines but only weakly inhibits monoamine uptake in vitro. Bupropion 0-9 monoamine oxidase A Rattus norvegicus 27-30 6312356-5 1983 Bupropion neither inhibits MAO (monoamine oxidase) nor releases biogenic amines but only weakly inhibits monoamine uptake in vitro. Bupropion 0-9 monoamine oxidase A Rattus norvegicus 32-49 6971560-7 1981 The ability of bupropion and mazindol to inhibit alpha-methylparatyrosine-induced prolactin secretion, and of nomifensine to inhibit reserpine-induced prolactin secretion, is consistent with other evidence that these agents are indirect dopamine (DA) agonists. Bupropion 15-24 prolactin Rattus norvegicus 82-91 316848-0 1979 Influence of bupropion HCl (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Bupropion 13-26 prolactin Homo sapiens 85-94 316848-0 1979 Influence of bupropion HCl (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Bupropion 28-38 prolactin Homo sapiens 85-94 34015277-5 2021 When assessing the impact of 2D6 phenotypes on bupropion mediated CYP 2D6 DDI in Chinese cancer population, we found that AUC increased by at least 60% in extensive metabolizers (EM) and 30% in IM. Bupropion 47-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 66-73 33905640-0 2021 Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Bupropion 39-48 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 29-35 33905640-1 2021 PURPOSE: The aim of this study was to investigate the potential dose-dependent CYP2D6 inhibition by bupropion (BUP) in patients with depression. Bupropion 100-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 33905640-1 2021 PURPOSE: The aim of this study was to investigate the potential dose-dependent CYP2D6 inhibition by bupropion (BUP) in patients with depression. Bupropion 111-114 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 33905640-9 2021 CONCLUSIONS: Bupropion exhibits a clear dose-dependent CYP2D6 inhibitory effect during treatment of patients with depression. Bupropion 13-22 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 55-61 33905640-11 2021 Half of the patients treated with high-dose BUP are converted to CYP2D6 PM phenotype. Bupropion 44-47 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 65-71 33739838-4 2021 Protein expression and intracellular unbound drug concentration (Kpuu) effects on the CLint were investigated for five prototypical probe substrates (bupropion-CYP2B6, diclofenac-CYP2C9, omeprazole-CYP2C19, bufuralol-CYP2D6, and midazolam-CYP3A4). Bupropion 150-159 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 160-166 33308914-4 2021 CASE 1: A 14-year-old boy intentionally ingested an estimated 30 bupropion 75-mg immediate-release tablets. Bupropion 65-74 immunoglobulin kappa variable 6D-41 (non-functional) Homo sapiens 8-12 33308914-8 2021 CASE 2: A 19-year-old woman intentionally ingested an estimated 53 bupropion 150-mg extended-release tablets. Bupropion 67-76 immunoglobulin kappa variable 2-28 Homo sapiens 8-12 33706003-4 2021 In an attempt to address this deficit, we will investigate the efficacy of bupropion vs. placebo as a smoking relapse prevention aid in postpartum women. Bupropion 75-84 activation induced cytidine deaminase Homo sapiens 129-132 32648334-0 2021 Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. Bupropion 74-83 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 97-116 32648334-1 2021 This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion. Bupropion 190-199 Janus kinase 1 Homo sapiens 87-101 32648334-1 2021 This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion. Bupropion 190-199 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 154-179 33275326-2 2021 This post-hoc analysis of four phase III, 56-week, randomized, controlled trials investigated if extended-release naltrexone and bupropion (NB) affects alanine aminotransferase (ALT) and Fibrosis Index (FIB-4) in adults with overweight or obesity. Bupropion 129-138 glutamic--pyruvic transaminase Homo sapiens 152-176 33599403-2 2021 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. Bupropion 56-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 33692710-0 2021 Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter. Bupropion 13-22 solute carrier family 6 member 3 Homo sapiens 68-88 33455055-7 2021 Coadministration of lemborexant with bupropion resulted in 49.9% and 45.5% decreases in S-bupropion Cmax and AUC0-inf , respectively.Comparison of estimated exposures for patients in phase 3 trials who were/were not receiving concomitant weak CYP3A inhibitors substantiated the DDI pharmacokinetic findings. Bupropion 37-46 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 243-248 33746741-8 2020 The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 muM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11. Bupropion 87-96 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 231-237 33746741-8 2020 The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 muM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11. Bupropion 87-96 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 242-249 33161206-0 2021 Corrigendum to "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation" [Biochem. Bupropion 90-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 125-131 33161206-0 2021 Corrigendum to "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation" [Biochem. Bupropion 90-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 172-178 33186562-2 2021 This study assessed the association between therapeutic response of bupropion and serum brain-derived neurotrophic factor (BDNF) and tumour necrosis factor-alpha (TNF-alpha) levels in patients with MDD. Bupropion 68-77 brain derived neurotrophic factor Homo sapiens 88-121 33186562-2 2021 This study assessed the association between therapeutic response of bupropion and serum brain-derived neurotrophic factor (BDNF) and tumour necrosis factor-alpha (TNF-alpha) levels in patients with MDD. Bupropion 68-77 brain derived neurotrophic factor Homo sapiens 123-127 33186562-8 2021 CONCLUSION: The results of our study suggest that bupropion SR monotherapy is effective and well tolerated in MDD patients with moderate to severe depression, and its therapeutic efficacy is accompanied by an increase in serum BDNF levels and a decrease in serum TNF-alpha levels. Bupropion 50-59 brain derived neurotrophic factor Homo sapiens 227-231 33186562-8 2021 CONCLUSION: The results of our study suggest that bupropion SR monotherapy is effective and well tolerated in MDD patients with moderate to severe depression, and its therapeutic efficacy is accompanied by an increase in serum BDNF levels and a decrease in serum TNF-alpha levels. Bupropion 50-59 tumor necrosis factor Homo sapiens 263-272 32221841-10 2020 CONCLUSION: The outcomes of the present study revealed that particularly activation or inhibition of the CB1 receptor function may augment the antidepressant activity of bupropion, whereas only inhibition of the CB1 receptor function manages to increase activity of moclobemide. Bupropion 170-179 cannabinoid receptor 1 (brain) Mus musculus 105-108 32475982-0 2020 Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. Bupropion 15-24 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 85-92 32475982-1 2020 Bupropion is hydroxylated to its primary active metabolite hydroxybupropion by cytochrome P450 enzyme CYP2B6. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 102-108 32475982-7 2020 The present case shows a reduced bupropion efficacy, which may be explained by a reduced active moiety of bupropion and its active metabolite hydroxybupropion, due to alternative hydroxylation pathways mediated by CYP2C19 in an individual with CYP2C19 rapid metabolizer status. Bupropion 33-42 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 214-221 32475982-7 2020 The present case shows a reduced bupropion efficacy, which may be explained by a reduced active moiety of bupropion and its active metabolite hydroxybupropion, due to alternative hydroxylation pathways mediated by CYP2C19 in an individual with CYP2C19 rapid metabolizer status. Bupropion 33-42 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 244-251 32475982-7 2020 The present case shows a reduced bupropion efficacy, which may be explained by a reduced active moiety of bupropion and its active metabolite hydroxybupropion, due to alternative hydroxylation pathways mediated by CYP2C19 in an individual with CYP2C19 rapid metabolizer status. Bupropion 106-115 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 214-221 32475982-7 2020 The present case shows a reduced bupropion efficacy, which may be explained by a reduced active moiety of bupropion and its active metabolite hydroxybupropion, due to alternative hydroxylation pathways mediated by CYP2C19 in an individual with CYP2C19 rapid metabolizer status. Bupropion 106-115 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 244-251 33238436-5 2020 Consistently, the in vitro metabolic kinetics (Vmax and CLint) of BUP (bupropion; a Cyp2b1 substrate) and TOL (tolbutamide; a Cyp2c11 substrate) were significantly changed by 1,25(OH)2D3 treatment in liver microsomes, but the kinetics of acetaminophen (an Ugt1a6/1a7/1a8 substrate) remained unaffected, consistent with Western blotting data for Ugt1a6. Bupropion 71-80 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 84-90 33238436-5 2020 Consistently, the in vitro metabolic kinetics (Vmax and CLint) of BUP (bupropion; a Cyp2b1 substrate) and TOL (tolbutamide; a Cyp2c11 substrate) were significantly changed by 1,25(OH)2D3 treatment in liver microsomes, but the kinetics of acetaminophen (an Ugt1a6/1a7/1a8 substrate) remained unaffected, consistent with Western blotting data for Ugt1a6. Bupropion 71-80 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 126-133 33238436-5 2020 Consistently, the in vitro metabolic kinetics (Vmax and CLint) of BUP (bupropion; a Cyp2b1 substrate) and TOL (tolbutamide; a Cyp2c11 substrate) were significantly changed by 1,25(OH)2D3 treatment in liver microsomes, but the kinetics of acetaminophen (an Ugt1a6/1a7/1a8 substrate) remained unaffected, consistent with Western blotting data for Ugt1a6. Bupropion 71-80 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 256-262 33124517-0 2020 Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. Bupropion 25-34 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 33124517-0 2020 Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. Bupropion 25-34 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 85-92 33124517-2 2020 Pharmacogenetic panel testing identified the patient as a carrier of the CYP2B6*6 allele, which has been associated with reduced bupropion metabolism and decreased concentrations of the pharmacologically active metabolite hydroxybupropion. Bupropion 129-138 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 73-79 33124517-4 2020 We propose a combined effect of the detected CYP2C19 and CYP2B6 genetic variants on bupropion metabolism. Bupropion 84-93 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 45-52 33124517-4 2020 We propose a combined effect of the detected CYP2C19 and CYP2B6 genetic variants on bupropion metabolism. Bupropion 84-93 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 32594336-0 2020 Bupropion Ameliorates Acetic Acid-Induced Colitis in Rat: the Involvement of the TLR4/NF-kB Signaling Pathway. Bupropion 0-9 toll-like receptor 4 Rattus norvegicus 81-85 32594336-0 2020 Bupropion Ameliorates Acetic Acid-Induced Colitis in Rat: the Involvement of the TLR4/NF-kB Signaling Pathway. Bupropion 0-9 RELA proto-oncogene, NF-kB subunit Rattus norvegicus 86-91 32594336-7 2020 In addition, the expression of TLR4 and NF-kB was decreased after colitis induction; however, treatment with dexamethasone (2 mg/kg) and bupropion (160 mg/kg) resulted in a significant decrease in their expression. Bupropion 137-146 toll-like receptor 4 Rattus norvegicus 31-35 32594336-7 2020 In addition, the expression of TLR4 and NF-kB was decreased after colitis induction; however, treatment with dexamethasone (2 mg/kg) and bupropion (160 mg/kg) resulted in a significant decrease in their expression. Bupropion 137-146 RELA proto-oncogene, NF-kB subunit Rattus norvegicus 40-45 32594336-8 2020 Regarding biochemical factors, following colitis induction, TNF-alpha level and MPO activity were increased; nevertheless, dexamethasone (2 mg/kg) and bupropion (160 mg/kg) decreased the TNF-alpha and MPO activity. Bupropion 151-160 tumor necrosis factor Rattus norvegicus 60-69 32594336-8 2020 Regarding biochemical factors, following colitis induction, TNF-alpha level and MPO activity were increased; nevertheless, dexamethasone (2 mg/kg) and bupropion (160 mg/kg) decreased the TNF-alpha and MPO activity. Bupropion 151-160 myeloperoxidase Rattus norvegicus 80-83 32594336-8 2020 Regarding biochemical factors, following colitis induction, TNF-alpha level and MPO activity were increased; nevertheless, dexamethasone (2 mg/kg) and bupropion (160 mg/kg) decreased the TNF-alpha and MPO activity. Bupropion 151-160 tumor necrosis factor Rattus norvegicus 187-196 32594336-8 2020 Regarding biochemical factors, following colitis induction, TNF-alpha level and MPO activity were increased; nevertheless, dexamethasone (2 mg/kg) and bupropion (160 mg/kg) decreased the TNF-alpha and MPO activity. Bupropion 151-160 myeloperoxidase Rattus norvegicus 201-204 32594336-9 2020 In conclusion, bupropion exerts anti-inflammatory influence through suppressing the TLR4 and NF-kB expression in the rat model of acute colitis. Bupropion 15-24 toll-like receptor 4 Rattus norvegicus 84-88 32594336-9 2020 In conclusion, bupropion exerts anti-inflammatory influence through suppressing the TLR4 and NF-kB expression in the rat model of acute colitis. Bupropion 15-24 RELA proto-oncogene, NF-kB subunit Rattus norvegicus 93-98 32459054-3 2020 In this study, we examined whether MDD patients with Met/Met, Met/Val, and Val/Val COMT genotypes differed in their response to bupropion in terms of depression scores. Bupropion 128-137 catechol-O-methyltransferase Homo sapiens 83-87 32459054-11 2020 CONCLUSION: High-dose bupropion is beneficial for MDD patients with Met/Val or Val/Val COMT genotypes, but not for patients with Met/Met genotype. Bupropion 22-31 catechol-O-methyltransferase Homo sapiens 87-91 32459054-12 2020 Prospective studies are necessary to replicate this pharmacodynamic relationship between bupropion and COMT genotypes and explore economic and clinical outcomes. Bupropion 89-98 catechol-O-methyltransferase Homo sapiens 103-107 32382785-7 2020 The DAT-selective inhibitor bupropion also fully blocked acid-induced ICSS depression and weight loss throughout all 7 days of treatment. Bupropion 28-37 solute carrier family 6 member 3 Rattus norvegicus 4-7 32238417-0 2020 Stereoselective bupropion hydroxylation by cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase genetic variants. Bupropion 16-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 59-65 32238417-0 2020 Stereoselective bupropion hydroxylation by cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase genetic variants. Bupropion 16-25 cytochrome p450 oxidoreductase Homo sapiens 70-100 32238417-1 2020 Bioactivation of the antidepressant and smoking cessation drug bupropion is catalyzed predominantly by cytochrome P4502B6 (CYP2B6). Bupropion 63-72 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-121 32238417-1 2020 Bioactivation of the antidepressant and smoking cessation drug bupropion is catalyzed predominantly by cytochrome P4502B6 (CYP2B6). Bupropion 63-72 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 123-129 32238417-3 2020 Bupropion hydroxylation is the canonical in vitro and in vivo probe for CYP2B6 activity. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 32238417-6 2020 Some CYP2B6 variants affect bupropion disposition. Bupropion 28-37 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 5-11 32238417-7 2020 This investigation evaluated the influence of several human CYP2B6 and POR genetic variants on stereoselective bupropion metabolism, using an insect cell coexpression system containing CYP2B6, POR and cytochrome b5. Bupropion 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 60-66 32238417-7 2020 This investigation evaluated the influence of several human CYP2B6 and POR genetic variants on stereoselective bupropion metabolism, using an insect cell coexpression system containing CYP2B6, POR and cytochrome b5. Bupropion 111-120 cytochrome p450 oxidoreductase Homo sapiens 71-74 32238417-10 2020 CYP2B6-catalyzed bupropion hydroxylation is stereoselective. Bupropion 17-26 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 32238417-12 2020 Established concordance between human bupropion hydroxylation in vitro and in vivo, together with these new results, suggests additional CYP2B6 variants may influence human bupropion disposition. Bupropion 38-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 137-143 32238417-12 2020 Established concordance between human bupropion hydroxylation in vitro and in vivo, together with these new results, suggests additional CYP2B6 variants may influence human bupropion disposition. Bupropion 173-182 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 137-143 32238417-13 2020 SIGNIFICANCE STATEMENT: Bupropion pharmacokinetics, metabolism and clinical effects are affected by the CYP2B6*6 polymorphism. Bupropion 24-33 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 104-110 32238417-14 2020 Other expressed CYP2B6 polymorphisms had diminished (*5, *6, *7, *9, *19, *26) or defective (*16, *18) in vitro bupropion hydroxylation. Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 32238417-16 2020 These CYP2B6 polymorphisms may portend diminished in vivo bupropion hydroxylation and predict additional clinically important variant alleles. Bupropion 58-67 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 6-12 32364297-3 2020 Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 muM, and the inhibition was confirmed using purified human CYP2B6. Bupropion 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 33-39 32364297-3 2020 Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 muM, and the inhibition was confirmed using purified human CYP2B6. Bupropion 50-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 157-163 32106832-0 2020 Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. Bupropion 23-32 complement C1q like 1 Homo sapiens 36-58 31587004-11 2020 Pan inhibitions of WZ35 on rat CYP3A2, CYP2B1, CYP2C11, CYP2D1, and -CYP2E1 were observed by detecting probe substrates (midazolam, bupropion, tolbutamide, dextromethorphan, chlorzoxazone) and metabolites accordingly. Bupropion 132-141 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 69-75 31669972-5 2019 Compared with varenicline monotherapy, combination treatment with varenicline and bupropion could significantly improve the abstinence rate at the end of treatment (RR 1.153, 95% CI 1.019 to 1.305, P=0.024). Bupropion 82-91 ribonucleotide reductase catalytic subunit M1 Homo sapiens 165-169 31698552-7 2019 BUP dose-dependently occupied DAT at considerable levels. Bupropion 0-3 solute carrier family 6 member 3 Rattus norvegicus 30-33 30724802-4 2019 We hypothesized that the DA transporter-selective uptake inhibitor bupropion would block depression of nesting behavior produced by intraperitoneal injection of lactic acid, whereas selective serotonin transporter-selective citalopram, norepinephrine transporter-selective nisoxetine, and the mixed action selective serotonin transporter/norepinephrine transporter inhibitor milnacipran would be ineffective. Bupropion 67-76 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 25-39 30724802-4 2019 We hypothesized that the DA transporter-selective uptake inhibitor bupropion would block depression of nesting behavior produced by intraperitoneal injection of lactic acid, whereas selective serotonin transporter-selective citalopram, norepinephrine transporter-selective nisoxetine, and the mixed action selective serotonin transporter/norepinephrine transporter inhibitor milnacipran would be ineffective. Bupropion 67-76 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 Mus musculus 338-364 31361666-0 2019 Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 39-59 31361666-1 2019 OBJECTIVE: The objective of this study was to report long-lasting effects of bupropion on brain dopamine transporter (DAT) in a patient with depression and parkinsonism. Bupropion 77-86 solute carrier family 6 member 3 Homo sapiens 96-116 31361666-1 2019 OBJECTIVE: The objective of this study was to report long-lasting effects of bupropion on brain dopamine transporter (DAT) in a patient with depression and parkinsonism. Bupropion 77-86 solute carrier family 6 member 3 Homo sapiens 118-121 31361666-9 2019 CONCLUSIONS: Bupropion has previously generally been discontinued 1 week prior DAT imaging, which meets the recommended, albeit arbitrary, time interval of 5 plasma clearance half-lives before the scan. Bupropion 13-22 solute carrier family 6 member 3 Homo sapiens 79-82 31361666-10 2019 One-week discontinuation of bupropion before DAT imaging may be insufficiently short. Bupropion 28-37 solute carrier family 6 member 3 Homo sapiens 45-48 31311925-5 2019 For example, we identify CHRNA9 with 12 PPIs (e.g., ERBB2) can be a therapeutic target and find its anti-metastasis agent, bupropion, for treatment in nicotine-induced breast cancer. Bupropion 123-132 cholinergic receptor nicotinic alpha 9 subunit Homo sapiens 25-31 31311925-5 2019 For example, we identify CHRNA9 with 12 PPIs (e.g., ERBB2) can be a therapeutic target and find its anti-metastasis agent, bupropion, for treatment in nicotine-induced breast cancer. Bupropion 123-132 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-57 31009648-7 2019 The DA reuptake inhibitors (methylphenidate, cocaine, and bupropion) inhibited DA uptake by WT hDAT most potently, followed by amphetamine-type stimulants [4-fluoroamphetamine (4-FA), amphetamine and MDMA], selective serotonin reuptake inhibitors (SSRI; fluoxetine and citalopram) and arylcyclohexylamines [methoxetamine (MXE) and ketamine]. Bupropion 58-67 solute carrier family 6 member 3 Homo sapiens 95-99 31009648-8 2019 Compared to DA uptake by WT hDAT, bupropion, methylphenidate, cocaine, and MXE less potently inhibited DA uptake by T356 M hDAT, while citalopram more potently inhibited uptake. Bupropion 34-43 solute carrier family 6 member 3 Homo sapiens 123-127 30578565-0 2019 Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation. Bupropion 35-44 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 30578565-2 2019 The cytochrome P450 2B6 gene (CYP2B6) encodes CYP2B6 enzyme that has been found to mediate the hydroxylation of bupropion, a smoking cessation aid. Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-23 30578565-2 2019 The cytochrome P450 2B6 gene (CYP2B6) encodes CYP2B6 enzyme that has been found to mediate the hydroxylation of bupropion, a smoking cessation aid. Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 30-36 30578565-2 2019 The cytochrome P450 2B6 gene (CYP2B6) encodes CYP2B6 enzyme that has been found to mediate the hydroxylation of bupropion, a smoking cessation aid. Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 46-52 30578565-3 2019 CYP2B6 exhibits a range of polymorphic variants that alter the pharmacokinetics and pharmacodynamics of bupropion. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 30578565-4 2019 Genetic variations in CYP2B6 may influence the risk of adverse effects or efficacy of treatment with bupropion. Bupropion 101-110 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 22-28 30578565-9 2019 RESULTS: There is strong literature evidence to prove that CYP2B6 polymorphisms affect pharmacokinetic and pharmacodynamic properties of bupropion, thus affecting the therapeutic outcome of smoking cessation therapy. Bupropion 137-146 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 59-65 30552947-1 2019 The objective of the present study is to investigate the role of alpha4, alpha5, alpha6 or beta2 nAChR subunits in the antidepressant-like effect of bupropion. Bupropion 149-158 immunoglobulin (CD79A) binding protein 1 Mus musculus 65-87 30552947-1 2019 The objective of the present study is to investigate the role of alpha4, alpha5, alpha6 or beta2 nAChR subunits in the antidepressant-like effect of bupropion. Bupropion 149-158 hemoglobin, beta adult minor chain Mus musculus 91-96 30552947-2 2019 Adult male mice were treated with subcutaneous acute doses of bupropion (3 and 10 mg/kg) 30 min before the forced swim test (FST) in alpha4, alpha5, alpha6, or beta2 nAChR subunit knockout (KO) and wild-type (WT) mice. Bupropion 62-71 hemoglobin, beta adult minor chain Mus musculus 160-165 30552947-5 2019 Bupropion significantly decreased immobility time and increased climbing time in the alpha4, alpha6 and beta2 nAChR KO mice in comparison to WT littermates, indicating that lack of these nAChR subunits enhanced antidepressant effects of bupropion. Bupropion 0-9 immunoglobulin (CD79A) binding protein 1 Mus musculus 85-99 30552947-5 2019 Bupropion significantly decreased immobility time and increased climbing time in the alpha4, alpha6 and beta2 nAChR KO mice in comparison to WT littermates, indicating that lack of these nAChR subunits enhanced antidepressant effects of bupropion. Bupropion 0-9 hemoglobin, beta adult minor chain Mus musculus 104-109 30552947-9 2019 Taken together, the present study provides evidence on the involvement of alpha4*, alpha6*, and beta2* (* indicates possible presence of other subunits) nAChRs in the antidepressant-like effects of bupropion in the FST. Bupropion 198-207 hemoglobin, beta adult minor chain Mus musculus 96-101 30929417-5 2019 Naltrexone/bupropion stimulates POMC neurons through bupropion; this stimulation is augmented by blocking the autoinhibitory mechanism of POMC with naltrexone. Bupropion 11-20 proopiomelanocortin Homo sapiens 32-36 30929417-5 2019 Naltrexone/bupropion stimulates POMC neurons through bupropion; this stimulation is augmented by blocking the autoinhibitory mechanism of POMC with naltrexone. Bupropion 11-20 proopiomelanocortin Homo sapiens 138-142 30929417-5 2019 Naltrexone/bupropion stimulates POMC neurons through bupropion; this stimulation is augmented by blocking the autoinhibitory mechanism of POMC with naltrexone. Bupropion 53-62 proopiomelanocortin Homo sapiens 32-36 30929417-5 2019 Naltrexone/bupropion stimulates POMC neurons through bupropion; this stimulation is augmented by blocking the autoinhibitory mechanism of POMC with naltrexone. Bupropion 53-62 proopiomelanocortin Homo sapiens 138-142 30842914-12 2019 The commonly used dose of 30 mg daily may have been too low to have an effect; additionally, the most frequently utilized select antidepressant, bupropion, has moderately less CYP2D6 inhibition than fluoxetine and paroxetine. Bupropion 145-154 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 176-182 30472588-2 2019 In this study, we used a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and N-acetyltransferase-2 (NAT2) in plasma. Bupropion 37-46 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 96-102 30472588-2 2019 In this study, we used a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and N-acetyltransferase-2 (NAT2) in plasma. Bupropion 37-46 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 104-110 30472588-2 2019 In this study, we used a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and N-acetyltransferase-2 (NAT2) in plasma. Bupropion 37-46 N-acetyltransferase 2 Homo sapiens 115-136 30472588-2 2019 In this study, we used a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and N-acetyltransferase-2 (NAT2) in plasma. Bupropion 37-46 N-acetyltransferase 2 Homo sapiens 138-142 30472588-14 2019 CONCLUSIONS: This study advocates the use of a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and NAT2, which is important in determining therapeutic dose levels of anti-HIV and anti-TB drugs in HIV/AIDS-TB coinfections. Bupropion 59-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 118-124 30472588-14 2019 CONCLUSIONS: This study advocates the use of a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and NAT2, which is important in determining therapeutic dose levels of anti-HIV and anti-TB drugs in HIV/AIDS-TB coinfections. Bupropion 59-68 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 126-132 30472588-14 2019 CONCLUSIONS: This study advocates the use of a cocktail of bupropion, losartan and dapsone for in vivo phenotyping of CYP2B6, CYP2C9 and NAT2, which is important in determining therapeutic dose levels of anti-HIV and anti-TB drugs in HIV/AIDS-TB coinfections. Bupropion 59-68 N-acetyltransferase 2 Homo sapiens 137-141 30312638-5 2019 The agent with 5-HT6 antagonistic properties (PZ-668) revealed an anti-immobility action of bupropion (primarily) and reboxetine in interaction studies. Bupropion 92-101 5-hydroxytryptamine receptor 6 Rattus norvegicus 15-20 29756345-0 2019 Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. Bupropion 57-66 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 29756345-2 2019 This investigation determined the influence of CYP2B6 allelic variants on clinical concentrations and metabolism of bupropion enantiomers. Bupropion 116-125 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 29756345-7 2019 Hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances, was lower in CYP2B6*6/*6 but not CYP2B6*1/*6 compared with CYP2B6*1/*1 genotypes, and numerically greater in CYP2B6*4 carriers. Bupropion 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 164-170 29756345-7 2019 Hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances, was lower in CYP2B6*6/*6 but not CYP2B6*1/*6 compared with CYP2B6*1/*1 genotypes, and numerically greater in CYP2B6*4 carriers. Bupropion 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 184-190 29756345-7 2019 Hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances, was lower in CYP2B6*6/*6 but not CYP2B6*1/*6 compared with CYP2B6*1/*1 genotypes, and numerically greater in CYP2B6*4 carriers. Bupropion 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 184-190 29756345-7 2019 Hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances, was lower in CYP2B6*6/*6 but not CYP2B6*1/*6 compared with CYP2B6*1/*1 genotypes, and numerically greater in CYP2B6*4 carriers. Bupropion 22-31 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 184-190 29756345-7 2019 Hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances, was lower in CYP2B6*6/*6 but not CYP2B6*1/*6 compared with CYP2B6*1/*1 genotypes, and numerically greater in CYP2B6*4 carriers. Bupropion 71-80 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 164-170 29756345-9 2019 The results show that clinical hydroxylation of both bupropion enantiomers was equivalently influenced by CYP2B6 allelic variation. Bupropion 53-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 106-112 29756345-10 2019 CYP2B6 polymorphisms affect S-bupropion bioactivation, which may affect therapeutic outcomes. Bupropion 28-39 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 30662880-0 2018 Neuroprotective Effects of Forced Exercise and Bupropion on Chronic Methamphetamine-induced Cognitive Impairment via Modulation of cAMP Response Element-binding Protein/Brain-derived Neurotrophic Factor Signaling Pathway, Oxidative Stress, and Inflammatory Biomarkers in Rats. Bupropion 47-56 cAMP responsive element binding protein 1 Rattus norvegicus 131-168 30662880-0 2018 Neuroprotective Effects of Forced Exercise and Bupropion on Chronic Methamphetamine-induced Cognitive Impairment via Modulation of cAMP Response Element-binding Protein/Brain-derived Neurotrophic Factor Signaling Pathway, Oxidative Stress, and Inflammatory Biomarkers in Rats. Bupropion 47-56 brain-derived neurotrophic factor Rattus norvegicus 169-202 30662880-8 2018 Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins" expression with P < 0.001 in methamphetamine treated rats. Bupropion 0-9 cAMP responsive element binding protein 1 Rattus norvegicus 92-96 30662880-8 2018 Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins" expression with P < 0.001 in methamphetamine treated rats. Bupropion 0-9 brain-derived neurotrophic factor Rattus norvegicus 124-128 30662880-8 2018 Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins" expression with P < 0.001 in methamphetamine treated rats. Bupropion 31-40 cAMP responsive element binding protein 1 Rattus norvegicus 92-96 30662880-8 2018 Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins" expression with P < 0.001 in methamphetamine treated rats. Bupropion 31-40 brain-derived neurotrophic factor Rattus norvegicus 124-128 30219678-12 2018 The metabolic capacity of CYP450 was evaluated using five probe drugs, phenacetin, tolbutamide, metoprolol, midazolam, and bupropion. Bupropion 123-132 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 26-32 29870591-0 2018 Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers. Bupropion 111-120 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 33-39 29870591-0 2018 Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers. Bupropion 111-120 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 45-51 30201214-1 2018 Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ). Bupropion 173-182 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-45 30201214-1 2018 Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ). Bupropion 173-182 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 interleukin 6 Rattus norvegicus 143-157 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 interleukin 6 Rattus norvegicus 159-163 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 NFE2 like bZIP transcription factor 2 Rattus norvegicus 199-242 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 NFE2 like bZIP transcription factor 2 Rattus norvegicus 244-248 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 tumor necrosis factor Rattus norvegicus 254-281 30081056-8 2018 Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-alpha (TNF-alpha). Bupropion 0-9 tumor necrosis factor Rattus norvegicus 283-292 30112578-10 2018 Both clonidine and bupropion attenuated the effects of 2-DG on CPA and CORT, but only bupropion reversed suppression of locomotion. Bupropion 19-28 cortistatin Rattus norvegicus 71-75 28876959-6 2018 Furthermore, the metabolism studies also suggested specific involvement of CYP2B6 pathway in the stereoselective hydroxylation of bupropion to R,R-hydroxybupropion, which was considered as a better marker for CYP2B6 activity. Bupropion 130-139 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 75-81 28876959-6 2018 Furthermore, the metabolism studies also suggested specific involvement of CYP2B6 pathway in the stereoselective hydroxylation of bupropion to R,R-hydroxybupropion, which was considered as a better marker for CYP2B6 activity. Bupropion 130-139 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 209-215 28876959-8 2018 Other significant learnings were: (1) understanding the in vivo CYP2D6 inhibitory potential of bupropion with respect to the chirality of parent drug and the metabolites; (2) the potential involvement of bupropion and metabolites towards significant down regulation of CYP2D6 mRNA; (3) significant in vivo CYP2D6 inhibitory activity (86%) exhibited by R,R-hydroxybupropion and threohydrobupropion. Bupropion 95-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 64-70 28876959-8 2018 Other significant learnings were: (1) understanding the in vivo CYP2D6 inhibitory potential of bupropion with respect to the chirality of parent drug and the metabolites; (2) the potential involvement of bupropion and metabolites towards significant down regulation of CYP2D6 mRNA; (3) significant in vivo CYP2D6 inhibitory activity (86%) exhibited by R,R-hydroxybupropion and threohydrobupropion. Bupropion 95-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 269-275 28876959-8 2018 Other significant learnings were: (1) understanding the in vivo CYP2D6 inhibitory potential of bupropion with respect to the chirality of parent drug and the metabolites; (2) the potential involvement of bupropion and metabolites towards significant down regulation of CYP2D6 mRNA; (3) significant in vivo CYP2D6 inhibitory activity (86%) exhibited by R,R-hydroxybupropion and threohydrobupropion. Bupropion 95-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 269-275 29496989-6 2018 Results: The half-maximal inhibitory concentrations of desipramine, escitalopram, venlafaxine, and bupropion on 131I-MIBG cellular uptake were 11.9 nM, 7.5 muM, 4.92 muM, and 12.9 muM, respectively. Bupropion 99-108 latexin Homo sapiens 156-159 29496989-6 2018 Results: The half-maximal inhibitory concentrations of desipramine, escitalopram, venlafaxine, and bupropion on 131I-MIBG cellular uptake were 11.9 nM, 7.5 muM, 4.92 muM, and 12.9 muM, respectively. Bupropion 99-108 latexin Homo sapiens 166-169 29496989-6 2018 Results: The half-maximal inhibitory concentrations of desipramine, escitalopram, venlafaxine, and bupropion on 131I-MIBG cellular uptake were 11.9 nM, 7.5 muM, 4.92 muM, and 12.9 muM, respectively. Bupropion 99-108 latexin Homo sapiens 166-169 28737446-9 2018 The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.24, 0.28, 0.15, 0.45, 0.46, 0.42 and 0.54, respectively, in HLM determined by chemical inhibition method. Bupropion 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 28737446-10 2018 The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.46, 0.17, 0.15, 0.60, 0.51, 0.66 and 0.77, respectively, in HLM determined by chemical inhibition method in the presence of BSA (0.5% w/v). Bupropion 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 28737446-12 2018 Bupropion metabolism is majorly mediated by CYP2C19 (0.41) with a minor contribution from CYP2B6 (0.16) in the presence of BSA. Bupropion 0-9 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 44-51 28737446-13 2018 Ticlopidine is a time-dependent inhibitor of both CYP2B6 and CYP2C19 that can inhibit the bupropion metabolism by 50-60%. Bupropion 90-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 50-56 28737446-13 2018 Ticlopidine is a time-dependent inhibitor of both CYP2B6 and CYP2C19 that can inhibit the bupropion metabolism by 50-60%. Bupropion 90-99 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 61-68 29936730-0 2018 Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study Background: Cancer-related fatigue (CRF) is very common and can be experienced at all stages of disease and insurvivors. Bupropion 18-27 complement C1q like 1 Homo sapiens 127-149 30026780-6 2018 Furthermore, isotope uptake study showed that Delta3,2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Bupropion 271-280 solute carrier family 6 member 3 Homo sapiens 104-124 30026780-6 2018 Furthermore, isotope uptake study showed that Delta3,2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Bupropion 271-280 solute carrier family 6 member 3 Homo sapiens 126-129 30026780-6 2018 Furthermore, isotope uptake study showed that Delta3,2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Bupropion 271-280 solute carrier family 6 member 2 Homo sapiens 135-161 30026780-6 2018 Furthermore, isotope uptake study showed that Delta3,2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Bupropion 271-280 solute carrier family 6 member 2 Homo sapiens 163-166 29637923-0 2018 Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects. Bupropion 70-79 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 36-42 30166913-1 2018 A rapid, simple and accurate micellar HPLC-method was adopted and validated for concurrent quantification of naltrexone hydrochloride (NTX) and bupropion hydrochloride (BUP). Bupropion 144-167 COMM domain containing 3 Homo sapiens 169-172 29267251-0 2017 Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Bupropion 42-51 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 75-81 29267251-9 2017 The simulation suggests that bupropion and its metabolites contribute to the DDI between bupropion and CYP2D6 substrates. Bupropion 29-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 103-109 28253826-8 2017 This result indicates that the 14 day-intragastric administration of codeine may inhibit the metabolism of bupropion (CYP2B1) and midazolam (CYP3A2) in rat. Bupropion 107-116 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 118-124 29196725-3 2017 To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation therapies, we carried out an association study on 337 smokers who underwent pharmacotherapy with varenicline, bupropion, nicotine replacement therapy (NRT) alone, or NRT plus bupropion. Bupropion 223-232 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 44-49 29196725-3 2017 To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation therapies, we carried out an association study on 337 smokers who underwent pharmacotherapy with varenicline, bupropion, nicotine replacement therapy (NRT) alone, or NRT plus bupropion. Bupropion 288-297 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 44-49 28698115-0 2017 Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Bupropion 57-66 interleukin 17A Homo sapiens 0-14 28698115-8 2017 Higher baseline IL-17 level was associated with greater reduction in depression severity (effect size=0.78, p=0.008) in the bupropion-SSRI but not the other two treatment arms. Bupropion 124-133 interleukin 17A Homo sapiens 16-21 28698115-10 2017 CONCLUSION: Higher baseline levels of IL-17 are selectively associated with greater symptomatic reduction in depressed patients treated with bupropion-SSRI combination. Bupropion 141-150 interleukin 17A Homo sapiens 38-43 29089770-2 2017 Bupropion, a norepinephrine-dopamine reuptake inhibitor, shows weak dopamine transporter (DAT) occupancy. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 68-88 29089770-2 2017 Bupropion, a norepinephrine-dopamine reuptake inhibitor, shows weak dopamine transporter (DAT) occupancy. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 90-93 29089770-14 2017 However, the interpretation of the SPECT image might be biased by the use of certain drugs such as bupropion for its binding to DAT. Bupropion 99-108 solute carrier family 6 member 3 Homo sapiens 128-131 29089770-15 2017 Bupropion may decrease the Tc-99m TRODAT-1 binding to DAT. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 37-40 29054049-6 2017 Concomitant use of CYP inhibitors (e.g. paroxetine, fluoxetine and bupropion) or inducers (e.g. carbamazepine, phenobarbital and phenytoin) could counteract the clinical effect or trigger side effects of analgesics in the same manner as genetically determined differences in CYP2D6-mediated metabolism of many opioids. Bupropion 67-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 275-281 28220701-1 2017 Bupropion (1), an alpha-aminophenone uptake inhibitor at plasma membrane transporters for dopamine (DAT) and norepinephrine (NET), is a widely prescribed antidepressant and smoking cessation aid. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 100-103 28468305-4 2017 Fargesin negligibly inhibited CYP1A2-catalyzed phenacetin O-deethylation, CYP2A6-catalyzed coumarin 7-hydroxylation, CYP2B6-catalyzed bupropion hydroxylation, and CYP2D6-catalyzed bufuralol 1"-hydroxylation at 100 muM in human liver microsomes. Bupropion 134-143 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 117-123 28187400-9 2017 Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). Bupropion 106-115 C-reactive protein Homo sapiens 16-19 28187400-11 2017 The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for <1mg/L and Bupropion-SSRI for >=1mg/L) was 53.1%, with a number needed to treat of 8.6. Bupropion 101-110 C-reactive protein Homo sapiens 34-37 27900470-0 2017 Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. Bupropion 174-183 glutamate receptor, ionotropic, NMDA2B (epsilon 2) Mus musculus 45-49 27046219-8 2017 Duloxetine and bupropion are both cytochrome P450 2D6 inhibitors that may result in a higher level of hydroxybupropion. Bupropion 15-24 cytochrome P450 2D6 Homo sapiens 34-53 27836670-0 2017 In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Bupropion 74-83 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 109-115 27836670-0 2017 In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Bupropion 74-83 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 156-162 27836670-1 2017 Bupropion is a widely used antidepressant and smoking cessation aid and a strong inhibitor of CYP2D6 in vivo. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 94-100 27836670-3 2017 Four primary metabolites of bupropion, threo- and erythro-hydrobupropion and R,R- and S,S-OH-bupropion, circulate at higher concentrations than the parent drug and are believed to contribute to the efficacy and side effects of bupropion as well as to the CYP2D6 inhibition. Bupropion 28-37 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 255-261 27836670-4 2017 However, bupropion and its metabolites are only weak inhibitors of CYP2D6 in vitro, and the magnitude of the in vivo drug-drug interactions (DDI) caused by bupropion cannot be explained by the in vitro data even when CYP2D6 inhibition by the metabolites is accounted for. Bupropion 9-18 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 67-73 27836670-4 2017 However, bupropion and its metabolites are only weak inhibitors of CYP2D6 in vitro, and the magnitude of the in vivo drug-drug interactions (DDI) caused by bupropion cannot be explained by the in vitro data even when CYP2D6 inhibition by the metabolites is accounted for. Bupropion 9-18 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 217-223 27836670-6 2017 Bupropion and its metabolites were found to inhibit CYP2D6 stereoselectively with up to 10-fold difference in inhibition potency between enantiomers. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 52-58 27836670-8 2017 In HepG2 cells and in plated human hepatocytes bupropion and its metabolites were found to significantly downregulate CYP2D6 mRNA in a concentration dependent manner. Bupropion 47-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-124 27836670-9 2017 The in vivo DDI was quantitatively predicted by significant down-regulation of CYP2D6 mRNA and reversible inhibition of CYP2D6 by bupropion and its metabolites. Bupropion 130-139 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 120-126 27273149-0 2017 Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects. Bupropion 101-110 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 67-82 27528039-4 2016 Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Bupropion 187-196 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 165-171 27528039-4 2016 Therefore, the aims of this study were to determine the steady-state pharmacokinetics of bupropion during pregnancy and the effect of functional genetic variants of CYP2B6 and CYP2C19 on bupropion pharmacokinetics in pregnant women. Bupropion 187-196 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 176-183 27528039-7 2016 In contrast, pregnancy-induced increase in CYP2B6-catalyzed bupropion hydroxylation did not impact the plasma levels of OHBUP, probably due to a higher rate of OHBUP glucuronidation, and renal elimination associated with pregnancy. Bupropion 60-69 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 43-49 27555326-4 2016 After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect. Bupropion 111-120 solute carrier family 6 member 3 Homo sapiens 31-34 27555326-4 2016 After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect. Bupropion 111-120 solute carrier family 6 member 3 Homo sapiens 73-76 27555326-4 2016 After screening a set of known DAT ligands for their ability to increase DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression, whereas others, including cocaine and methylphenidate, had no effect. Bupropion 111-120 solute carrier family 6 member 3 Homo sapiens 73-76 27555326-5 2016 Bupropion and ibogaine increased wild type DAT protein levels and also promoted maturation of the endoplasmic reticulum (ER)-retained DAT mutant K590A. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 43-46 27555326-5 2016 Bupropion and ibogaine increased wild type DAT protein levels and also promoted maturation of the endoplasmic reticulum (ER)-retained DAT mutant K590A. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 134-137 27555326-7 2016 Furthermore, knockdown of coat protein complex II (COPII) component SEC24D, which is important in the ER export of wild type DAT, also blocked the rescue effects of bupropion and ibogaine. Bupropion 165-174 SEC24 homolog D, COPII coat complex component Homo sapiens 68-74 27555326-7 2016 Furthermore, knockdown of coat protein complex II (COPII) component SEC24D, which is important in the ER export of wild type DAT, also blocked the rescue effects of bupropion and ibogaine. Bupropion 165-174 solute carrier family 6 member 3 Homo sapiens 125-128 27555326-8 2016 These data suggest that bupropion and ibogaine promote maturation of DAT by acting as pharmacological chaperones in the ER. Bupropion 24-33 solute carrier family 6 member 3 Homo sapiens 69-72 27994356-1 2016 BACKGROUND: We aimed to compare the efficacy of fixed doses of bupropion and ropinirole and iron alone for the treatment of restless legs syndrome (RLS) and to look for the tolerability of these medications. Bupropion 63-72 RLS1 Homo sapiens 148-151 27783296-0 2016 Effects of Single Administration of Bupropion on Carboxypeptidase E Activity in Structures of Rat Brain. Bupropion 36-45 carboxypeptidase E Rattus norvegicus 49-67 27783296-3 2016 Single injection of bupropion induced long-lasting changes in carboxypeptidase E activity in all brain structures. Bupropion 20-29 carboxypeptidase E Rattus norvegicus 62-80 27422672-6 2016 Although bupropion and efavirenz have been used and are recommended by regulatory agencies as clinical CYP2B6 probe substrates for DDI studies, CYP3A4 contributes to the metabolism of both probes and is induced by all reference CYP2B6 inducers. Bupropion 9-18 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 27495292-5 2016 In humans, the fraction of bupropion metabolized (fm) to the CYP2B6 probe metabolite OH-bupropion is 5-16%, but ticlopidine increases bupropion exposure by 61%, suggesting a 40% CYP2B6 and/or CYP2C19 fm for bupropion. Bupropion 27-36 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 61-67 27495292-5 2016 In humans, the fraction of bupropion metabolized (fm) to the CYP2B6 probe metabolite OH-bupropion is 5-16%, but ticlopidine increases bupropion exposure by 61%, suggesting a 40% CYP2B6 and/or CYP2C19 fm for bupropion. Bupropion 27-36 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 178-184 27495292-5 2016 In humans, the fraction of bupropion metabolized (fm) to the CYP2B6 probe metabolite OH-bupropion is 5-16%, but ticlopidine increases bupropion exposure by 61%, suggesting a 40% CYP2B6 and/or CYP2C19 fm for bupropion. Bupropion 27-36 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 192-199 27495292-5 2016 In humans, the fraction of bupropion metabolized (fm) to the CYP2B6 probe metabolite OH-bupropion is 5-16%, but ticlopidine increases bupropion exposure by 61%, suggesting a 40% CYP2B6 and/or CYP2C19 fm for bupropion. Bupropion 88-97 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 61-67 27495292-5 2016 In humans, the fraction of bupropion metabolized (fm) to the CYP2B6 probe metabolite OH-bupropion is 5-16%, but ticlopidine increases bupropion exposure by 61%, suggesting a 40% CYP2B6 and/or CYP2C19 fm for bupropion. Bupropion 88-97 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 61-67 27495292-6 2016 Yet, the CYP2C19 contribution to bupropion clearance has not been defined, and the enzymes contributing to overall bupropion metabolite formation have not been fully characterized. Bupropion 33-42 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 9-16 27495292-7 2016 The aim of this study was to characterize the stereoselective metabolism of bupropion in vitro to explain the stereoselective pharmacokinetics and the effect of drug-drug interactions (DDIs) and CYP2C19 pharmacogenetics on bupropion exposure. Bupropion 76-85 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 195-202 27495292-9 2016 The fm,CYP2B6 was predicted to be 21%, and the fm,CYP2C19, 6% for racemic bupropion. Bupropion 74-83 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 50-57 27439448-3 2016 CYP2B6 activity was measured by bupropion hydroxylation with LC/MS/MS. Bupropion 32-41 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 27439448-4 2016 The ratio of hydroxybupropion versus bupropion (AUC_hyd/AUC_bup) in terms of area under the time-concentration curve (AUC) was used to represent the CYP2B6 activity. Bupropion 20-29 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 149-155 27622933-8 2016 Gene sets associated with long-term depression, circadian rhythm and vascular endothelial growth factor (VEGF) pathway were enriched in the bupropion analysis. Bupropion 140-149 vascular endothelial growth factor A Homo sapiens 69-103 27622933-8 2016 Gene sets associated with long-term depression, circadian rhythm and vascular endothelial growth factor (VEGF) pathway were enriched in the bupropion analysis. Bupropion 140-149 vascular endothelial growth factor A Homo sapiens 105-109 27387538-5 2016 Of the CYP enzymes tested, CYP2B6-catalyzed bupropion 6-hydroxylation was inhibited by S002-333 (IC50 ~ 9.25 +- 2.46 muM) in a stereoselective manner with (S)-isomer showing potent inhibition (IC50 ~ 5.28 +- 1.25 muM) in contrast to (R)-isomer which showed negligible inhibition on CYP2B6 activity (IC50 > 50 muM). Bupropion 44-53 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 7-10 27387538-5 2016 Of the CYP enzymes tested, CYP2B6-catalyzed bupropion 6-hydroxylation was inhibited by S002-333 (IC50 ~ 9.25 +- 2.46 muM) in a stereoselective manner with (S)-isomer showing potent inhibition (IC50 ~ 5.28 +- 1.25 muM) in contrast to (R)-isomer which showed negligible inhibition on CYP2B6 activity (IC50 > 50 muM). Bupropion 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 27387538-5 2016 Of the CYP enzymes tested, CYP2B6-catalyzed bupropion 6-hydroxylation was inhibited by S002-333 (IC50 ~ 9.25 +- 2.46 muM) in a stereoselective manner with (S)-isomer showing potent inhibition (IC50 ~ 5.28 +- 1.25 muM) in contrast to (R)-isomer which showed negligible inhibition on CYP2B6 activity (IC50 > 50 muM). Bupropion 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 282-288 27255113-10 2016 In summary, to our knowledge, this is the first comprehensive report to provide novel insight into mechanisms underlying bupropion disposition by detailing the stereoselective pharmacokinetics of individual bupropion metabolites, which will enhance clinical understanding of bupropion"s effects and DDIs with CYP2D6. Bupropion 121-130 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 309-315 27255113-10 2016 In summary, to our knowledge, this is the first comprehensive report to provide novel insight into mechanisms underlying bupropion disposition by detailing the stereoselective pharmacokinetics of individual bupropion metabolites, which will enhance clinical understanding of bupropion"s effects and DDIs with CYP2D6. Bupropion 207-216 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 309-315 27255113-10 2016 In summary, to our knowledge, this is the first comprehensive report to provide novel insight into mechanisms underlying bupropion disposition by detailing the stereoselective pharmacokinetics of individual bupropion metabolites, which will enhance clinical understanding of bupropion"s effects and DDIs with CYP2D6. Bupropion 207-216 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 309-315 27321734-7 2016 Consistently, the enzyme-kinetic and pharmacokinetic parameters for CYP2B1-mediated bupropion metabolism were considerably reduced in MCD diet-fed rats; however, they were also similar between the HF diet-fed and control rats. Bupropion 84-93 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 68-74 27435752-6 2016 Next, independent DDI studies with substrates of CYP3A4 (maraviroc, atazanavir, and clarithromycin) and CYP2B6 (bupropion) verified the induction components of the model (area under the curve [AUC] ratios within 1.0-1.7-fold of observed). Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 104-110 27382354-8 2016 Acetaminophen, ibuprofen, nabumetone, and bupropion inhibited TRESK, but had no effect on TREK-2. Bupropion 42-51 potassium two pore domain channel subfamily K member 18 Homo sapiens 62-67 27660681-1 2016 Bupropion is a widely used antidepressant and the recommended CYP2B6 probe drug. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 62-68 27128896-4 2016 Aschantin at 100 microM negligibly inhibited CYP1A2-mediated phenacetin O-de-ethylation, CYP2A6-mediated coumarin 7-hydroxylation, CYP2B6-mediated bupropion hydroxylation, and CYP2D6-mediated bufuralol 1"-hydroxylation. Bupropion 147-156 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 131-137 26594837-10 2016 From the network meta-analysis, both bupropion and varenicline were more effective than placebo [odds ratio (OR) = 4.51, 95% credible interval (CrI) = 1.45-14.04 and OR = 5.17, 95% CrI = 1.78-15.06, respectively]. Bupropion 37-46 EP300 interacting inhibitor of differentiation 1 Homo sapiens 125-152 26886209-11 2016 Overall, these results suggest DAT inhibition as the major mechanism of the methamphetamine-like "agonist" effects of bupropion, although nACh receptor antagonism appeared, at least partially, to contribute. Bupropion 118-127 solute carrier family 6 member 3 Macaca mulatta 31-34 26802129-1 2016 Bupropion is a widely used antidepressant and smoking cessation aid in addition to being one of two US Food and Drug Administration-recommended probe substrates for evaluation of cytochrome P450 2B6 activity. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 179-198 26802129-6 2016 Elimination pathways were further characterized using an expressed UDP-glucuronosyl transferase (UGT) panel with bupropion enantiomers (both individual and racemic) as substrates. Bupropion 113-122 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 97-100 27518170-7 2016 CONCLUSIONS: These results demonstrated that the effect of bupropion on CYP2D6 activity was responsible for an increased systemic exposure to atomoxetine (5.1-fold) and also for a decreased exposure to its main metabolite (1.5-fold). Bupropion 59-68 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 72-78 26967321-7 2016 Bupropion reduced the Cmax and AUC24 of the CYP2D6-dependently formed metabolite stereoisomers of DHMA 3-sulfate, DHMA 4-sulfate, and 4-hydroxy-3-methoxymethamphetamine (HMMA sulfate and HMMA glucuronide) by approximately 40%. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 44-50 26580670-0 2016 Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Bupropion 124-133 cytochrome p450 oxidoreductase Homo sapiens 24-54 26580670-0 2016 Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Bupropion 124-133 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 80-99 26580670-2 2016 The aim of this study was to investigate whether single-nucleotide polymorphisms in the POR gene were correlated with interindividual variations in CYP2B6 activity, as measured by bupropion hydroxylation. Bupropion 180-189 cytochrome p450 oxidoreductase Homo sapiens 88-91 26580670-2 2016 The aim of this study was to investigate whether single-nucleotide polymorphisms in the POR gene were correlated with interindividual variations in CYP2B6 activity, as measured by bupropion hydroxylation. Bupropion 180-189 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 148-154 26580670-4 2016 The activity of CYP2B6 was evaluated on the basis of the area under the time-concentration curve (AUC) ratio of hydroxybupropion versus bupropion (AUC_hyd/AUC_bup). Bupropion 119-128 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 152-161 cytochrome p450 oxidoreductase Homo sapiens 65-68 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 152-161 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 120-126 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 342-351 cytochrome p450 oxidoreductase Homo sapiens 65-68 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 342-351 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 120-126 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 342-351 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 196-202 26580670-9 2016 CONCLUSION: These results indicate, for the first time, that the POR g.6593A>G polymorphism significantly influences CYP2B6 activity, as measured by bupropion hydroxylation, in humans, and the CYP2B6*6 and POR g.6593A>G polymorphisms might be considered simultaneously for the individualized therapy with CYP2B6 substrate drugs such as bupropion. Bupropion 342-351 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 196-202 27300331-1 2016 BACKGROUND/AIMS: The study aimed at investigating the effects of multiple-dose bupropion (potent inhibitor of CYP2D6) on the pharmacokinetics (PKs) of single-dose nebivolol (CYP2D6 substrate) and to evaluate the clinical relevance of this potential drug interaction. Bupropion 79-88 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 110-116 26681005-1 2015 CYP2B6 is a highly polymorphic isoenzyme involved in the metabolism of many drugs including cyclophosphamide, bupropion, and efavirenz. Bupropion 110-119 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26481532-4 2015 OBJECTIVE AND METHODS: In the present study we investigated whether acute or chronic treatment with imipramine, escitalopram, reboxetine and bupropion would cause changes in CREB, BDNF, TrkB and GPR39-Zn(2+) receptor proteins (measured by Western Blot) in the frontal cortex of mice fed with a low-zinc diet. Bupropion 141-150 cAMP responsive element binding protein 1 Mus musculus 174-178 26481532-4 2015 OBJECTIVE AND METHODS: In the present study we investigated whether acute or chronic treatment with imipramine, escitalopram, reboxetine and bupropion would cause changes in CREB, BDNF, TrkB and GPR39-Zn(2+) receptor proteins (measured by Western Blot) in the frontal cortex of mice fed with a low-zinc diet. Bupropion 141-150 brain derived neurotrophic factor Mus musculus 180-184 26481532-4 2015 OBJECTIVE AND METHODS: In the present study we investigated whether acute or chronic treatment with imipramine, escitalopram, reboxetine and bupropion would cause changes in CREB, BDNF, TrkB and GPR39-Zn(2+) receptor proteins (measured by Western Blot) in the frontal cortex of mice fed with a low-zinc diet. Bupropion 141-150 neurotrophic tyrosine kinase, receptor, type 2 Mus musculus 186-190 26481532-4 2015 OBJECTIVE AND METHODS: In the present study we investigated whether acute or chronic treatment with imipramine, escitalopram, reboxetine and bupropion would cause changes in CREB, BDNF, TrkB and GPR39-Zn(2+) receptor proteins (measured by Western Blot) in the frontal cortex of mice fed with a low-zinc diet. Bupropion 141-150 G protein-coupled receptor 39 Mus musculus 195-200 25589680-0 2015 Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior? Bupropion 23-32 activation induced cytidine deaminase Homo sapiens 33-36 25565674-0 2015 Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data. Bupropion 59-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 10-16 25565674-2 2015 Previous studies have reported conflicting impact of the CYP2B6*6 variant allele on the formation of hydroxybupropion from bupropion. Bupropion 108-117 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 25565674-3 2015 The aim of this study was to clarify the effect of CYP2B6*6 and secondarily CYP2D6 genotype on steady-state serum concentrations of bupropion and hydroxybupropion in a large population of psychiatric patients. Bupropion 132-141 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 51-57 25565674-3 2015 The aim of this study was to clarify the effect of CYP2B6*6 and secondarily CYP2D6 genotype on steady-state serum concentrations of bupropion and hydroxybupropion in a large population of psychiatric patients. Bupropion 132-141 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 76-82 25565674-11 2015 CONCLUSIONS: This study shows that the CYP2B6*6 variant allele is associated with significantly reduced formation of the active bupropion metabolite in psychiatric patients. Bupropion 128-137 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 39-45 26153084-0 2015 CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Bupropion 78-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 26153084-1 2015 BACKGROUND: Previous studies suggested that polymorphisms in the CYP2B6 gene (which encodes an isoenzyme that metabolizes bupropion) and in the ANKK1 gene (which is located in the ANKK1/DRD2 gene cluster) might influence response to therapy. Bupropion 122-131 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 65-71 26153084-1 2015 BACKGROUND: Previous studies suggested that polymorphisms in the CYP2B6 gene (which encodes an isoenzyme that metabolizes bupropion) and in the ANKK1 gene (which is located in the ANKK1/DRD2 gene cluster) might influence response to therapy. Bupropion 122-131 ankyrin repeat and kinase domain containing 1 Homo sapiens 144-149 26153084-7 2015 RESULTS: Patients with CYP2B6 rs2279343 wild-type AA genotype had higher success rate (48.0 %) compared with patients carrying AG or GG genotypes (CYP2B6*4 variant) (35.5 %) on bupropion therapy. Bupropion 177-186 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 26153084-10 2015 CONCLUSION: We showed that patients with CYP2B6*4 (rs2279343) variant had lower success rate with bupropion. Bupropion 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-47 26153084-11 2015 Likely, the CYP2B6*4 variant, which leads to a rapid predicted metabolic phenotype for the isoenzyme, influences the pharmacological activity of bupropion. Bupropion 145-154 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 26153084-12 2015 Our finding suggests that CYP2B6*4 may be an important genetic marker for individualized bupropion pharmacotherapy. Bupropion 89-98 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-32 25904761-1 2015 Bupropion"s metabolism and the formation of hydroxybupropion in the liver by cytochrome P450 2B6 (CYP2B6) has been extensively studied; however, the metabolism and formation of erythro/threohydrobupropion in the liver and intestine by carbonyl reductases (CR) has not been well characterized. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 77-96 25904761-1 2015 Bupropion"s metabolism and the formation of hydroxybupropion in the liver by cytochrome P450 2B6 (CYP2B6) has been extensively studied; however, the metabolism and formation of erythro/threohydrobupropion in the liver and intestine by carbonyl reductases (CR) has not been well characterized. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 98-104 25904761-2 2015 The purpose of this investigation was to compare the relative contribution of the two metabolism pathways of bupropion (by CYP2B6 and CR) in the subcellular fractions of liver and intestine and to identify the CRs responsible for erythro/threohydrobupropion formation in the liver and the intestine. Bupropion 109-118 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 123-129 25836357-5 2015 Sub-effective dose of ascorbic acid combined with sub-effective doses of fluoxetine, imipramine, bupropion, MK-801 or 7-nitroindazole produced a synergistic antidepressant-like effect in mice exposed or not to TNF-alpha. Bupropion 97-106 tumor necrosis factor Mus musculus 210-219 26055126-8 2015 RESULTS: MA strongly inhibited CYP1A2-mediated phenacetin O-deethylation and CYP2B6-mediated bupropion hydroxylation with IC50 values of 3.0 and 3.9 microM, respectively, while it did not significantly inhibit other CYPs. Bupropion 93-102 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 77-83 25801005-8 2015 CYP2B6 mRNA and activity (bupropion N-demethylation) were induced by several antiretrovirals, as were CYP3A4 mRNA and protein expression, but only indinavir increased CYP3A activity (alfentanil dealkylation). Bupropion 26-35 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 25323625-0 2015 The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Bupropion 206-215 solute carrier family 18 member A2 Homo sapiens 4-10 25656918-0 2015 Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Bupropion 65-74 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 49-55 25656918-1 2015 The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase (MAO) inhibitors and to predict the drug-drug interaction potential of monoamine oxidase inhibitors as perpetrators of drug interaction. Bupropion 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 82-88 25656918-2 2015 Human liver microsomal CYP2B6 activities were investigated using bupropion hydroxylation as probe substrate marker. Bupropion 65-74 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 25409894-4 2015 Function of the transgenic CYP2B6 was first studied using bupropion as a probe substrate. Bupropion 58-67 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 25489907-1 2015 The extensively polymorphic CYP2B6 gene metabolizes endogenous and exogenous compounds, among which are nicotine and bupropion, although its contribution to the systemic metabolism of nicotine still remains controversial. Bupropion 117-126 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 25318994-7 2015 Among them, bupropion and nifedipine showed high selectivity to CYP2C76. Bupropion 12-21 cytochrome P450 family 2 subfamily C member 76 Macaca fascicularis 64-71 25318994-10 2015 These results suggest that monkey CYP2C76 contributes to bupropion hydroxylation and formation of different nifedipine oxidative metabolites as a result of its relatively large substrate cavity. Bupropion 57-66 cytochrome P450 family 2 subfamily C member 76 Macaca fascicularis 34-41 26415702-2 2015 CBR1 catalyzes the reduction of many xenobiotics, including important drugs (e.g. anthracyclines, nabumetone, bupropion, dolasetron) and harmful carbonyls and quinones. Bupropion 110-119 carbonyl reductase 1 Homo sapiens 0-4 26265436-6 2015 Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline. Bupropion 283-292 tryptophan hydroxylase 2 Homo sapiens 91-115 26265436-6 2015 Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline. Bupropion 283-292 tryptophan hydroxylase 2 Homo sapiens 117-121 26265436-6 2015 Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline. Bupropion 283-292 solute carrier family 6 member 4 Homo sapiens 131-152 26265436-6 2015 Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline. Bupropion 283-292 solute carrier family 6 member 4 Homo sapiens 154-160 25670957-3 2015 Despite of the theoretical relevancy, the antidepressant effect of bupropion in IFN-alpha-induced depression has never been studied. Bupropion 67-76 interferon alpha 1 Homo sapiens 80-89 25670957-7 2015 This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms. Bupropion 48-57 interferon alpha 1 Homo sapiens 83-92 25308323-0 2014 An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System. Bupropion 21-30 DDB1 and CUL4 associated factor 7 Homo sapiens 0-5 25187485-0 2014 Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Bupropion 61-70 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 17-24 25187485-4 2014 In vitro data suggested CYP2C19 could metabolize bupropion. Bupropion 49-58 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 24-31 25187485-5 2014 The current study investigated the impact of functional CYP2C19 genetic variants on bupropion pharmacokinetics and treatment outcomes. Bupropion 84-93 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 56-63 25187485-6 2014 In 42 healthy volunteers, CYP2C19*2 (a reduced activity allele) was associated with higher bupropion area under the plasma concentration-time curve (AUC), but similar hydroxybupropion AUC. Bupropion 91-100 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 26-33 25187485-7 2014 The mean bupropion AUC was 771 versus 670 hours ng/ml in individuals with and without CYP2C19*2, respectively (P = 0.017). Bupropion 9-18 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 86-93 25187485-11 2014 In conclusion, our study reports the first in vivo evidence that reduced CYP2C19 activity significantly increases the steady-state exposure to bupropion and its reductive metabolites threohydrobupropion and erythrohydrobupropion. Bupropion 143-152 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 73-80 25016090-2 2014 The inhibitory activity of bupropion was studied on GH3-alpha7 cells by Ca2+ influx, as well as on neurons from the dorsal raphe nucleus and interneurons from the stratum radiatum of the hippocampal CA1 region by using a whole-cell voltage-clamp technique. Bupropion 27-36 carbonic anhydrase 2 Homo sapiens 72-75 25309681-5 2014 Compounds that were not found to be CYP2B6 substrates were still able to inhibit CYP2B6 activity toward a known substrate, bupropion, suggesting they do gain access to the CYP2B6 active site. Bupropion 123-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 36-42 25309681-5 2014 Compounds that were not found to be CYP2B6 substrates were still able to inhibit CYP2B6 activity toward a known substrate, bupropion, suggesting they do gain access to the CYP2B6 active site. Bupropion 123-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-87 25309681-5 2014 Compounds that were not found to be CYP2B6 substrates were still able to inhibit CYP2B6 activity toward a known substrate, bupropion, suggesting they do gain access to the CYP2B6 active site. Bupropion 123-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-87 24452068-13 2014 Potential sex differences in bupropion pharmacokinetics, probably due to differential activities of CYP2B6, should be taken into account when the drug is prescribed. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 100-106 25073092-7 2014 Fluoxetine and bupropion suppressed LPS-induced IP-10 expression in monocytes, and they had no cytotoxic effects. Bupropion 15-24 C-X-C motif chemokine ligand 10 Homo sapiens 48-53 25073092-9 2014 Fluoxetine and bupropion could not only treat depression but also reduce Th1-related chemokine IP-10 production in human monocytes. Bupropion 15-24 negative elongation factor complex member C/D Homo sapiens 73-76 25073092-9 2014 Fluoxetine and bupropion could not only treat depression but also reduce Th1-related chemokine IP-10 production in human monocytes. Bupropion 15-24 C-X-C motif chemokine ligand 10 Homo sapiens 95-100 24436229-6 2014 Bupropion and hydroxybupropion (HBUP) significantly stimulated H-OATP4C1 mediated transport of [(3) H]-DIG. Bupropion 0-9 solute carrier organic anion transporter family, member 4C1 Rattus norvegicus 65-72 24436229-10 2014 Surprisingly, bupropion significantly inhibited r-Oatp4c1 mediated transport of [(3) H]-DIG at clinically relevant unbound plasma concentrations of BUP or those observed in the rat study, while HBUP or TBUP did not. Bupropion 14-23 solute carrier organic anion transporter family, member 4C1 Rattus norvegicus 50-57 24436229-11 2014 These data support our hypothesis that at clinically relevant plasma concentrations, bupropion and its metabolites activate H-OATP4C1 mediated DIG tubular secretion, and could possibly explain the increase in digoxin renal clearance produced by bupropion. Bupropion 85-94 solute carrier organic anion transporter family, member 4C1 Rattus norvegicus 126-133 24436229-11 2014 These data support our hypothesis that at clinically relevant plasma concentrations, bupropion and its metabolites activate H-OATP4C1 mediated DIG tubular secretion, and could possibly explain the increase in digoxin renal clearance produced by bupropion. Bupropion 245-254 solute carrier organic anion transporter family, member 4C1 Rattus norvegicus 126-133 24436229-12 2014 While bupropion increased digoxin renal clearance in the rat, it appeared to do so by inhibiting r-Oatp4c1-mediated digoxin renal reabsorption. Bupropion 6-15 solute carrier organic anion transporter family, member 4C1 Rattus norvegicus 99-106 24658455-9 2014 CYP2B6 suppression by LY2090314 is not expected clinically, with a projected <1% decrease in hepatic enzyme activity and <1% decrease in hydroxybupropion exposure following bupropion coadministration. Bupropion 150-159 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 24878537-9 2014 This data coupled to the reduced DAT and NET system in vitro activity described in paper 1 would suggest that the N-methyl derivative of bupropion may have potential as an oral prodrug of bupropion in humans. Bupropion 137-146 solute carrier family 6 member 3 Homo sapiens 33-36 23924756-1 2014 OBJECTIVE: The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood. Bupropion 109-118 proopiomelanocortin Homo sapiens 216-236 23924756-1 2014 OBJECTIVE: The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood. Bupropion 109-118 proopiomelanocortin Homo sapiens 238-242 23924756-1 2014 OBJECTIVE: The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood. Bupropion 109-118 proopiomelanocortin Homo sapiens 305-309 24709946-9 2014 Second, we show that this behavior is enhanced by treatment with the dopamine reuptake inhibitor, bupropion, in both hlh-17 and dat-1 animals, a result suggesting that SWIP behavior is regulated via a mechanism that is both dependent on and independent of DAT-1. Bupropion 98-107 Helix-loop-helix protein 17 Caenorhabditis elegans 117-123 24709946-9 2014 Second, we show that this behavior is enhanced by treatment with the dopamine reuptake inhibitor, bupropion, in both hlh-17 and dat-1 animals, a result suggesting that SWIP behavior is regulated via a mechanism that is both dependent on and independent of DAT-1. Bupropion 98-107 Sodium-dependent dopamine transporter Caenorhabditis elegans 128-133 24709946-9 2014 Second, we show that this behavior is enhanced by treatment with the dopamine reuptake inhibitor, bupropion, in both hlh-17 and dat-1 animals, a result suggesting that SWIP behavior is regulated via a mechanism that is both dependent on and independent of DAT-1. Bupropion 98-107 Sodium-dependent dopamine transporter Caenorhabditis elegans 256-261 24396053-8 2014 CYP2D6 inhibition with paroxetine, fluoxetine, bupropion and methadone significantly decreased the fraction of morphine excreted. Bupropion 47-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 24423593-2 2014 P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 microl) using methanol. Bupropion 70-79 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 84-90 24088726-10 2014 Moreover this study provides the first direct evidence that 11beta-hydroxysteroid dehydrogenase 1, AKR1C1, AKR1C2, AKR1C3 and CBR1 participate in the reducing biotransformation of bupropion in vitro. Bupropion 180-189 aldo-keto reductase family 1 member C1 Homo sapiens 99-105 24088726-10 2014 Moreover this study provides the first direct evidence that 11beta-hydroxysteroid dehydrogenase 1, AKR1C1, AKR1C2, AKR1C3 and CBR1 participate in the reducing biotransformation of bupropion in vitro. Bupropion 180-189 aldo-keto reductase family 1 member C2 Homo sapiens 107-113 24088726-10 2014 Moreover this study provides the first direct evidence that 11beta-hydroxysteroid dehydrogenase 1, AKR1C1, AKR1C2, AKR1C3 and CBR1 participate in the reducing biotransformation of bupropion in vitro. Bupropion 180-189 aldo-keto reductase family 1 member C3 Homo sapiens 115-121 24088726-10 2014 Moreover this study provides the first direct evidence that 11beta-hydroxysteroid dehydrogenase 1, AKR1C1, AKR1C2, AKR1C3 and CBR1 participate in the reducing biotransformation of bupropion in vitro. Bupropion 180-189 carbonyl reductase 1 Homo sapiens 126-130 23818090-7 2013 Hydroxy bupropion formation was used as a more sensitive marker of CYP2B6 activity than bupropion kinetics. Bupropion 8-17 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 67-73 24260284-1 2013 The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Bupropion 208-217 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-23 24260284-1 2013 The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Bupropion 208-217 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 25-31 24260284-1 2013 The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6, but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Bupropion 208-217 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 24237812-9 2013 The woman was also taking fluoxetine and bupropion which are strong inhibitors of CYP 2D6. Bupropion 41-50 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 82-89 23981664-0 2013 The beta4 nicotinic receptor subunit modulates the chronic antidepressant effect mediated by bupropion. Bupropion 93-102 basic helix-loop-helix family, member e23 Mus musculus 4-9 23981664-1 2013 The objective of the current study is to investigate the role of the nicotinic receptor beta4 subunit in the antidepressant activity of bupropion. Bupropion 136-145 basic helix-loop-helix family, member e23 Mus musculus 88-93 23981664-5 2013 Our results indicate that: (1) the acute treatment with bupropion increases the swimming time (i.e., antidepressant effect) in beta4+/+ and beta4-/- mice from both genders, (2) the antidepressant effect after the chronic treatment is seen only in female beta4+/+ mice, and (3) the residual antidepressant effect of bupropion persists only in male beta4+/+ mice after one week withdrawal. Bupropion 56-65 basic helix-loop-helix family, member e23 Mus musculus 127-132 23981664-5 2013 Our results indicate that: (1) the acute treatment with bupropion increases the swimming time (i.e., antidepressant effect) in beta4+/+ and beta4-/- mice from both genders, (2) the antidepressant effect after the chronic treatment is seen only in female beta4+/+ mice, and (3) the residual antidepressant effect of bupropion persists only in male beta4+/+ mice after one week withdrawal. Bupropion 56-65 basic helix-loop-helix family, member e23 Mus musculus 140-145 23981664-5 2013 Our results indicate that: (1) the acute treatment with bupropion increases the swimming time (i.e., antidepressant effect) in beta4+/+ and beta4-/- mice from both genders, (2) the antidepressant effect after the chronic treatment is seen only in female beta4+/+ mice, and (3) the residual antidepressant effect of bupropion persists only in male beta4+/+ mice after one week withdrawal. Bupropion 56-65 basic helix-loop-helix family, member e23 Mus musculus 140-145 23981664-5 2013 Our results indicate that: (1) the acute treatment with bupropion increases the swimming time (i.e., antidepressant effect) in beta4+/+ and beta4-/- mice from both genders, (2) the antidepressant effect after the chronic treatment is seen only in female beta4+/+ mice, and (3) the residual antidepressant effect of bupropion persists only in male beta4+/+ mice after one week withdrawal. Bupropion 56-65 basic helix-loop-helix family, member e23 Mus musculus 140-145 23981664-6 2013 We conclude that the beta4 subunit plays a modulatory role in the chronic antidepressant effect mediated by bupropion, and that its effect is gender-specific. Bupropion 108-117 basic helix-loop-helix family, member e23 Mus musculus 21-26 23777987-3 2013 Sibutramine showed potent inhibition of CYP2B6-mediated bupropion 6-hydroxylation with an IC50 value of 1.61muM and Ki value of 0.466muM in a competitive manner at microsomal protein concentrations of 0.25mg/ml; this was 3.49-fold more potent than the typical CYP2B6 inhibitor thio-TEPA (Ki=1.59muM). Bupropion 56-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 24005963-4 2013 Honokiol also moderately inhibited CYP2B6-mediated bupropion hydroxylation and CYP2D6-mediated bufuralol 1"-hydroxylation with K(i) values of 17.5 and 12.0 muM, respectively. Bupropion 51-60 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 35-41 23804523-0 2013 Formation of threohydrobupropion from bupropion is dependent on 11beta-hydroxysteroid dehydrogenase 1. Bupropion 23-32 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 64-101 23804523-7 2013 Here, we used for the first time recombinant 11beta-HSD1 to assess its role in the carbonyl reduction of bupropion. Bupropion 105-114 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 45-56 23804523-8 2013 Furthermore, we applied human, rat, and mouse liver microsomes and a selective inhibitor to characterize species-specific differences and to estimate the relative contribution of 11beta-HSD1 to bupropion metabolism. Bupropion 194-203 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 179-190 23770308-6 2013 Furthermore, KA-induced c-Fos expression and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in the hippocampus were also reduced by bupropion pretreatment. Bupropion 152-161 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 24-29 23770308-6 2013 Furthermore, KA-induced c-Fos expression and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in the hippocampus were also reduced by bupropion pretreatment. Bupropion 152-161 mitogen activated protein kinase 3 Rattus norvegicus 45-86 23770308-6 2013 Furthermore, KA-induced c-Fos expression and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in the hippocampus were also reduced by bupropion pretreatment. Bupropion 152-161 mitogen activated protein kinase 3 Rattus norvegicus 88-94 23579386-6 2013 Interestingly, at the subthresold doses, flunarizine, nicardipine, amlodipine, verapamil, and bupropion, a nAChR antagonist, significantly reversed the nicotine improvement of memory acquisition, while flunarizine, verapamil, and bupropion attenuated the improvement of memory consolidation provoked by an acute injection of nicotine (0.035 mg/kg, s.c.). Bupropion 94-103 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 107-112 23212438-1 2013 INTRODUCTION: DRD4 Exon III Variable Number of Tandem Repeat (VNTR) variation was found to interact with bupropion to influence prospective smoking abstinence, in a recently published longitudinal analyses of N = 331 individuals from a randomized double-blind placebo-controlled trial of bupropion and intensive cognitive-behavioral mood management therapy. Bupropion 105-114 dopamine receptor D4 Homo sapiens 14-18 23212438-1 2013 INTRODUCTION: DRD4 Exon III Variable Number of Tandem Repeat (VNTR) variation was found to interact with bupropion to influence prospective smoking abstinence, in a recently published longitudinal analyses of N = 331 individuals from a randomized double-blind placebo-controlled trial of bupropion and intensive cognitive-behavioral mood management therapy. Bupropion 288-297 dopamine receptor D4 Homo sapiens 14-18 23953570-2 2013 Bupropion is an antidepressant known to inhibit TNF-alpha production. Bupropion 0-9 tumor necrosis factor Rattus norvegicus 48-57 23953570-9 2013 Bupropion in reduced intestinal I/R injury through immunomodulatory machanisms that involve inflammatory cytokines such as TNF-alpha. Bupropion 0-9 tumor necrosis factor Rattus norvegicus 123-132 23840296-0 2013 Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. Bupropion 81-90 nuclear receptor subfamily 1 group I member 2 Homo sapiens 20-39 23840296-0 2013 Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. Bupropion 81-90 nuclear receptor subfamily 1 group I member 2 Homo sapiens 41-44 23840296-0 2013 Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. Bupropion 81-90 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 50-56 23840296-8 2013 In conclusion, it is suggested that NR1I2 variants decrease the bupropion hydroxylation induced by SF treatment, particularly in CYP2B6*6 carriers. Bupropion 64-73 nuclear receptor subfamily 1 group I member 2 Homo sapiens 36-41 23840296-8 2013 In conclusion, it is suggested that NR1I2 variants decrease the bupropion hydroxylation induced by SF treatment, particularly in CYP2B6*6 carriers. Bupropion 64-73 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 129-135 23128516-9 2013 In a multivariate analysis of successful treatment predictors, compared with varenicline monotherapy, patients who used bupropion + SRI adjuvant treatment had an odds ratio (OR) of 5.05 (1.99-12.80) for a successful treatment response after 1-year follow-up, while patients who used bupropion or SRI had OR of 3.21 (1.68-6.14) and 3.58 (1.98-6.48), respectively. Bupropion 120-129 sorcin Homo sapiens 296-299 23128516-9 2013 In a multivariate analysis of successful treatment predictors, compared with varenicline monotherapy, patients who used bupropion + SRI adjuvant treatment had an odds ratio (OR) of 5.05 (1.99-12.80) for a successful treatment response after 1-year follow-up, while patients who used bupropion or SRI had OR of 3.21 (1.68-6.14) and 3.58 (1.98-6.48), respectively. Bupropion 283-292 sorcin Homo sapiens 132-135 23474197-4 2013 The present study shows the up-regulation of the GPR39 receptor protein level after escitalopram (by 290%), reboxetine (by 816%) and bupropion (by 272%), but not imipramine treatment. Bupropion 133-142 G protein-coupled receptor 39 Mus musculus 49-54 23672601-6 2013 We also show here that Slc6a17mRNA is up-regulated in animals subjected to short term food deprivation as well as animals treated with the serotonin reuptake inhibitor fluoxetine and the dopamine/noradrenaline reuptake inhibitor bupropion. Bupropion 229-238 solute carrier family 6 member 17 Rattus norvegicus 23-30 22947179-5 2013 Significant association (gene-wide correction) was observed for remission following treatment with bupropion for a SNP within the serotonin receptor 2A gene (HTR2A rs2770296, p(corrected)=0.02). Bupropion 99-108 5-hydroxytryptamine receptor 2A Homo sapiens 158-163 22947179-6 2013 Response to bupropion treatment was significantly associated with a SNP in the dopamine transporter gene (rs6347, p(corrected)=0.013). Bupropion 12-21 solute carrier family 6 member 3 Homo sapiens 79-99 22947179-10 2013 These results suggest a possible role for HTR2A in remission to bupropion treatment. Bupropion 64-73 5-hydroxytryptamine receptor 2A Homo sapiens 42-47 22947179-11 2013 In accordance with bupropion pharmacology, dopamine transporter may play a role in response. Bupropion 19-28 solute carrier family 6 member 3 Homo sapiens 43-63 23153057-3 2013 The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively. Bupropion 172-181 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 79-85 23153057-3 2013 The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively. Bupropion 172-181 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-93 23153057-3 2013 The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively. Bupropion 172-181 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 95-101 23153057-3 2013 The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively. Bupropion 172-181 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 106-112 23467454-3 2013 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. Bupropion 56-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 23238783-0 2013 The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Bupropion 56-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-43 23238783-0 2013 The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Bupropion 56-65 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 100-106 23238783-10 2013 These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion. Bupropion 171-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 23238783-10 2013 These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion. Bupropion 171-180 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 110-116 23238783-11 2013 The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups. Bupropion 4-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 69-75 23344581-0 2013 Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Bupropion 75-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 13-19 23344581-1 2013 BACKGROUND: Bupropion, an antidepressant and smoking cessation medication, is metabolized to hydroxybupropion (HB), an active metabolite, primarily by CYP2B6. Bupropion 12-21 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 151-157 23344581-2 2013 OBJECTIVES: To compare plasma concentrations of bupropion and metabolites at steady state in healthy volunteers with and without CYP2B6 genetic variants. Bupropion 48-57 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 129-135 23344581-6 2013 CONCLUSION: As HB is active and its steady-state concentrations are more than 10 times higher than bupropion, CYP2B6 variants are likely to affect pharmacological activity. Bupropion 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 110-116 23245243-8 2013 Due to substantial inter-substrate interaction, chlorzoxazone (CYP2E1) and bupropion (CYP2B6) were removed from the initial seven probes CYP cocktail assay. Bupropion 75-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-92 23011268-5 2013 Bupropion, but not fluoxetine or desipramine, was able to correct deficient social facilitation, social reward, and social novelty in DISC1-Q31L mutants, whereas all three ADs were able to improve social motivation and behavioral despair in DISC1-Q31L mutants. Bupropion 0-9 disrupted in schizophrenia 1 Mus musculus 134-139 23011268-5 2013 Bupropion, but not fluoxetine or desipramine, was able to correct deficient social facilitation, social reward, and social novelty in DISC1-Q31L mutants, whereas all three ADs were able to improve social motivation and behavioral despair in DISC1-Q31L mutants. Bupropion 0-9 disrupted in schizophrenia 1 Mus musculus 241-246 23011268-8 2013 Bupropion induced the greatest effect on CREB in DISC1-Q31L mutants, whereas all studied ADs corrected the reduced levels of beta-arrestin-1,2 and modestly ameliorated deficient spine density in this brain region. Bupropion 0-9 cAMP responsive element binding protein 1 Mus musculus 41-45 23011268-8 2013 Bupropion induced the greatest effect on CREB in DISC1-Q31L mutants, whereas all studied ADs corrected the reduced levels of beta-arrestin-1,2 and modestly ameliorated deficient spine density in this brain region. Bupropion 0-9 disrupted in schizophrenia 1 Mus musculus 49-54 23036826-8 2013 DAT binding was significantly decreased in the striatum after bupropion treatment. Bupropion 62-71 solute carrier family 6 member 3 Homo sapiens 0-3 23036826-11 2013 Depressed patients had a greater availability of DAT; it was decreased after bupropion treatment.Women seemed to have more DAT availability. Bupropion 77-86 solute carrier family 6 member 3 Homo sapiens 49-52 23036826-11 2013 Depressed patients had a greater availability of DAT; it was decreased after bupropion treatment.Women seemed to have more DAT availability. Bupropion 77-86 solute carrier family 6 member 3 Homo sapiens 123-126 23178527-3 2013 Here, we sought to characterize the interaction of amylin with naltrexone/bupropion on energy balance. Bupropion 74-83 islet amyloid polypeptide Rattus norvegicus 51-57 23648676-4 2013 In the present study, P450 metabolic activity was investigated in the small intestine of MacfaCAM and MacfaCHN, and cynomolgus macaques bred in Indonesia (MacfaIDN) using P450 substrates, including 7-ethoxyresorufin, coumarin, bupropion, paclitaxel, diclofenac, S-mephenytoin, bufuralol, chlorzoxazone, and testosterone. Bupropion 227-236 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 22-26 22519658-1 2012 AIMS: This study aimed to investigate the effect of metamizole on bupropion hydroxylation related to different CYP2B6 genotype groups in healthy volunteers. Bupropion 66-75 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 111-117 23149928-5 2012 Genetic variation in CYP2B6, the enzyme that metabolizes bupropion to hydroxybupropion, was identified as a significant source of variability in hydroxybupropion formation. Bupropion 57-66 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 22936314-2 2012 Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 22936314-6 2012 In standard inhibition assays, selegiline increased the K(m) of CYP2B6 for bupropion from 10 to 92 muM and decreased the k(cat) by ~50%. Bupropion 75-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 64-70 22940586-2 2012 Sildenafil, a selective PDE5 inhibitor, was shown to abolish the anti-immobility effects of bupropion, venlafaxine and s-citalopram in mice. Bupropion 92-101 phosphodiesterase 5A, cGMP-specific Mus musculus 24-28 23961363-3 2012 The prevalence of poor and rapid metabolizers was determined in the target population for the category of drugs metabolized by CYP2B6 by measuring plasma bupropion, a drug metabolized by CYP2B6, and its metabolite. Bupropion 154-163 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 127-133 23961363-5 2012 CYP2B6 activity was measured as hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of cutoff value of log (hydroxybupropion/bupropion). Bupropion 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 23961363-5 2012 CYP2B6 activity was measured as hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of cutoff value of log (hydroxybupropion/bupropion). Bupropion 49-58 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 23961363-8 2012 Cutoff value defined in this study can be used as a tool for evaluating the status of CYP2B6 using bupropion as a probe drug. Bupropion 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-92 22806583-8 2012 At their upper plasma concentrations, only three compounds, bupropion, nefazodone and clozapine, showed potential for inhibition, of about 18 % at hOCT2 (bupropion), about 22 % at hOCT3 (nefazodone) and of approximately 10 % at hOCT2 and hOCT3 (clozapine). Bupropion 60-69 POU class 2 homeobox 2 Homo sapiens 147-152 22806583-8 2012 At their upper plasma concentrations, only three compounds, bupropion, nefazodone and clozapine, showed potential for inhibition, of about 18 % at hOCT2 (bupropion), about 22 % at hOCT3 (nefazodone) and of approximately 10 % at hOCT2 and hOCT3 (clozapine). Bupropion 60-69 solute carrier family 22 member 3 Homo sapiens 180-185 22806583-8 2012 At their upper plasma concentrations, only three compounds, bupropion, nefazodone and clozapine, showed potential for inhibition, of about 18 % at hOCT2 (bupropion), about 22 % at hOCT3 (nefazodone) and of approximately 10 % at hOCT2 and hOCT3 (clozapine). Bupropion 60-69 POU class 2 homeobox 2 Homo sapiens 228-233 22806583-8 2012 At their upper plasma concentrations, only three compounds, bupropion, nefazodone and clozapine, showed potential for inhibition, of about 18 % at hOCT2 (bupropion), about 22 % at hOCT3 (nefazodone) and of approximately 10 % at hOCT2 and hOCT3 (clozapine). Bupropion 60-69 solute carrier family 22 member 3 Homo sapiens 238-243 22544011-9 2012 Bupropion had lower risks than several antidepressants in Cox models but not MSMs. Bupropion 0-9 cytochrome c oxidase subunit 8A Homo sapiens 58-61 22395730-5 2012 We demonstrated that, similar to cocaine, the DAT blockers nomifensine and bupropion were less effective at inhibiting dopamine uptake following cocaine SA. Bupropion 75-84 solute carrier family 6 member 3 Rattus norvegicus 46-49 22041458-6 2012 The top finding indicated that 10 SNPs in SACM1L mediated the effects of bupropion on sexual side-effects (p = 4.98 x 10(-7), q = 0.023). Bupropion 73-82 SAC1 like phosphatidylinositide phosphatase Homo sapiens 42-48 22339467-2 2012 CYP2B6 mediates oxidation of bupropion to hydroxybupropion, but the enzyme(s) catalyzing carbonyl reduction of bupropion to erythro- and threohydrobupropion in human liver is unknown. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 22339467-2 2012 CYP2B6 mediates oxidation of bupropion to hydroxybupropion, but the enzyme(s) catalyzing carbonyl reduction of bupropion to erythro- and threohydrobupropion in human liver is unknown. Bupropion 49-58 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 22232427-6 2012 In HLMs, CYP2B6*6/*6 genotype was associated with markedly lower V(max) (and moderate increase in K(m)) and thus lower Cl(int) values for efavirenz and bupropion metabolism, but no difference in catalytic properties was noted between CYP2B6*1/*1 and CYP2B6*1/*6 genotypes. Bupropion 152-161 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 9-15 22394379-3 2012 Based on inhibition of [(125)I]SADU-3-72 binding, SADU-3-72 binds with high affinity (IC(50) = 0.8 muM) to the Torpedo nAChR in the resting (closed channel) state and in the agonist-induced desensitized state, and bupropion binds to that site with 3-fold higher affinity in the desensitized (IC(50) = 1.2 muM) than in the resting state. Bupropion 214-223 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 119-124 22394379-8 2012 These results establish the presence of two distinct bupropion binding sites within the Torpedo nAChR transmembrane domain: a high affinity site at the middle (M2-9) of the ion channel and a second site near the extracellular end of alphaM1 within a previously described halothane (general anesthetic) binding pocket. Bupropion 53-62 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 96-101 22190694-6 2012 An unexpected and potentially clinically significant DDI was observed between DIG and the CYP2B6 probe, bupropion, which decreased DIG AUC(0-24 h) 1.6-fold and increased Cl(renal) 1.8-fold. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 21928040-10 2012 Also the plasma hydroxybupropion-to-bupropion ratio of AUC was increased by 27% in sertraline treated mice, indicative of increased CYP2B activity. Bupropion 23-32 cytochrome P450, family 2, subfamily b, polypeptide 10 Mus musculus 132-137 22119163-4 2012 Bupropion hydrochloride form 2 crystallizes in the orthorhombic space group Pbca with Z=8, a=27.2853(5)A, b=8.7184(3)A, c=12.0422(3)A, V=2864.7(1)A3, as centrosymmetric dimers, thanks to the presence of N-H...Cl interactions, and mu2-bridging chloride ions, each connected to two protonated amine moieties. Bupropion 0-23 PBCA Homo sapiens 76-80 22048466-6 2012 For varenicline, continuous abstinence (weeks 9-12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5, and CHRNA4) (OR=1.76; 95% CI: 1.23-2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.78; 95% CI: 1.27-2.50) (p<0.001). Bupropion 187-196 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 81-86 22048466-6 2012 For varenicline, continuous abstinence (weeks 9-12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5, and CHRNA4) (OR=1.76; 95% CI: 1.23-2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.78; 95% CI: 1.27-2.50) (p<0.001). Bupropion 187-196 cholinergic receptor nicotinic beta 2 subunit Homo sapiens 112-118 20661272-0 2012 Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Bupropion 62-71 dopamine receptor D4 Homo sapiens 0-20 21658141-0 2012 Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Bupropion 72-81 solute carrier family 6 member 4 Homo sapiens 24-45 21658141-1 2012 AIMS: We investigated whether variants in the serotonin transporter gene (SLC6A4) influence smoking cessation rates using antidepressant therapy (i.e. bupropion and nortriptyline). Bupropion 151-160 solute carrier family 6 member 4 Homo sapiens 46-67 21658141-8 2012 FINDINGS: Carriers of the 5-HTTLPR high-activity L-variant had higher prolonged cessation rates with bupropion than placebo [odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.01-2.05, P = 0.04]. Bupropion 101-110 solute carrier family 6 member 4 Homo sapiens 26-34 21658141-11 2012 CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels. Bupropion 13-22 solute carrier family 6 member 4 Homo sapiens 94-100 21658141-11 2012 CONCLUSIONS: Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high-activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels. Bupropion 13-22 solute carrier family 6 member 4 Homo sapiens 168-189 22119468-1 2012 Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4"-position of the aromatic ring. Bupropion 44-53 solute carrier family 6 member 3 Homo sapiens 73-93 22119468-1 2012 Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4"-position of the aromatic ring. Bupropion 44-53 solute carrier family 6 member 3 Homo sapiens 95-98 22119468-1 2012 Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4"-position of the aromatic ring. Bupropion 198-207 solute carrier family 6 member 3 Homo sapiens 73-93 22119468-1 2012 Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4"-position of the aromatic ring. Bupropion 198-207 solute carrier family 6 member 3 Homo sapiens 95-98 22119468-5 2012 Compound (+-)-[(125)I]-3 represents the first successful example of a DAT and nAChR photoaffinity ligand based on the bupropion scaffold. Bupropion 118-127 solute carrier family 6 member 3 Homo sapiens 70-73 22119468-5 2012 Compound (+-)-[(125)I]-3 represents the first successful example of a DAT and nAChR photoaffinity ligand based on the bupropion scaffold. Bupropion 118-127 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 78-83 22119468-6 2012 Such ligands are expected to assist in mapping bupropion-binding pockets within plasma membrane monoamine transporters and ligand-gated nAChR ion channels. Bupropion 47-56 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 136-141 22171584-10 2012 With regard to this, duloxetine and bupropion are moderate inhibitors of CYP2D6. Bupropion 36-45 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 73-79 21965622-0 2012 Bupropion hydroxylation as a selective marker of rat CYP2B1 catalytic activity. Bupropion 0-9 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 53-59 21965622-3 2012 The purpose of the present study was to establish bupropion (BUP) hydroxylation, but not BROD, as a selective in vitro marker of CYP2B1 catalytic activity. Bupropion 50-59 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 129-135 21965622-3 2012 The purpose of the present study was to establish bupropion (BUP) hydroxylation, but not BROD, as a selective in vitro marker of CYP2B1 catalytic activity. Bupropion 61-64 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 129-135 22653164-7 2012 The two intervention studies, conducted in patients on 9-week bupropion treatment and 6-month non-pharmacological treatment, reported that smoking cessation increased the adiponectin levels. Bupropion 62-71 adiponectin, C1Q and collagen domain containing Homo sapiens 171-182 25063334-7 2012 We also found that acute administration with bupropion rescued depressive-like behaviours in HD animals, possibly through dopamine D2/D3 receptor mechanisms. Bupropion 45-54 dopamine receptor D2 Mus musculus 122-145 22719896-4 2012 Surprisingly, both mutants, Y181D and A287P in POR completely inhibited the CYP3A4 activity with testosterone, while the catalytic activity of CYP2B6 with bupropion was reduced to approximately ~70% of wild-type activity by Y181D and A287P mutations. Bupropion 155-164 cytochrome p450 oxidoreductase Homo sapiens 47-50 22719896-4 2012 Surprisingly, both mutants, Y181D and A287P in POR completely inhibited the CYP3A4 activity with testosterone, while the catalytic activity of CYP2B6 with bupropion was reduced to approximately ~70% of wild-type activity by Y181D and A287P mutations. Bupropion 155-164 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 143-149 21301907-1 2011 Mounting evidence thus far indicates that human cytochrome P450 2B6 (CYP2B6), an enzyme expressed at a relatively low level functionally, is primarily responsible for the metabolism of several clinically relevant drugs, including propofol, efavirenz, bupropion, mephobarbital, and the propofol analog 2,6-di-sec-butyl phenol. Bupropion 251-260 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 48-67 21301907-1 2011 Mounting evidence thus far indicates that human cytochrome P450 2B6 (CYP2B6), an enzyme expressed at a relatively low level functionally, is primarily responsible for the metabolism of several clinically relevant drugs, including propofol, efavirenz, bupropion, mephobarbital, and the propofol analog 2,6-di-sec-butyl phenol. Bupropion 251-260 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 69-75 21925601-12 2011 Time-course activities of CYP2B1/2, 2D1, and 3A1 were also investigated by using bupropion, bufuralol, and midazolam as respective substrates. Bupropion 81-90 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 26-39 21946596-6 2011 The same degree of increase is expected for the two other potent CYP2D6 inhibitors in the class, fluoxetine and bupropion. Bupropion 112-121 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 65-71 21659470-0 2011 Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-43 21659470-0 2011 Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 45-51 21659470-0 2011 Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 54-60 21659470-0 2011 Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 54-60 21659470-1 2011 In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 21659470-1 2011 In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 21659470-1 2011 In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 21659470-1 2011 In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 21659470-3 2011 The steady-state turnover rates for the hydroxylation of bupropion and efavirenz and the O-deethylation of 7-EFC showed that these mutations significantly alter the catalytic activities of CYP2B6. Bupropion 57-66 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 189-195 21659470-4 2011 It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions. Bupropion 105-114 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 21659470-4 2011 It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions. Bupropion 105-114 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 148-154 21354251-5 2011 Treatment of the cells with a toxic concentration of bupropion (100mug/mL) induced the phosphorylation of eukaryotic initiation factor alpha (EIF-2alpha), c-JUN N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) within 1h, which later declined to baseline levels. Bupropion 53-62 eukaryotic translation initiation factor 2A Homo sapiens 142-152 21354251-5 2011 Treatment of the cells with a toxic concentration of bupropion (100mug/mL) induced the phosphorylation of eukaryotic initiation factor alpha (EIF-2alpha), c-JUN N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) within 1h, which later declined to baseline levels. Bupropion 53-62 mitogen-activated protein kinase 8 Homo sapiens 155-178 21354251-5 2011 Treatment of the cells with a toxic concentration of bupropion (100mug/mL) induced the phosphorylation of eukaryotic initiation factor alpha (EIF-2alpha), c-JUN N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) within 1h, which later declined to baseline levels. Bupropion 53-62 mitogen-activated protein kinase 8 Homo sapiens 180-183 21354251-5 2011 Treatment of the cells with a toxic concentration of bupropion (100mug/mL) induced the phosphorylation of eukaryotic initiation factor alpha (EIF-2alpha), c-JUN N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) within 1h, which later declined to baseline levels. Bupropion 53-62 mitogen-activated protein kinase 14 Homo sapiens 190-193 21354251-7 2011 Bupropion caused mitochondrial cytochrome c release and activated caspases 9, 8, and 3 in a time-dependent manner. Bupropion 0-9 cytochrome c, somatic Homo sapiens 31-43 21354251-7 2011 Bupropion caused mitochondrial cytochrome c release and activated caspases 9, 8, and 3 in a time-dependent manner. Bupropion 0-9 caspase 9 Homo sapiens 66-86 21354251-9 2011 Bupropion also induced the mRNA expression of the death receptors DR4 (TRAILR1) and DR5 (TRAILR2). Bupropion 0-9 TNF receptor superfamily member 10a Homo sapiens 66-69 21354251-9 2011 Bupropion also induced the mRNA expression of the death receptors DR4 (TRAILR1) and DR5 (TRAILR2). Bupropion 0-9 TNF receptor superfamily member 10a Homo sapiens 71-78 21354251-9 2011 Bupropion also induced the mRNA expression of the death receptors DR4 (TRAILR1) and DR5 (TRAILR2). Bupropion 0-9 TNF receptor superfamily member 10b Homo sapiens 84-87 21354251-9 2011 Bupropion also induced the mRNA expression of the death receptors DR4 (TRAILR1) and DR5 (TRAILR2). Bupropion 0-9 TNF receptor superfamily member 10b Homo sapiens 89-96 21354251-11 2011 Taken together, our data indicate that bupropion activates caspase 3 through the induction of endoplasmic reticulum stress responses and activation of JNK, and consequently induces apoptotic cell death in SH-SY5Y cells. Bupropion 39-48 caspase 3 Homo sapiens 59-68 21354251-11 2011 Taken together, our data indicate that bupropion activates caspase 3 through the induction of endoplasmic reticulum stress responses and activation of JNK, and consequently induces apoptotic cell death in SH-SY5Y cells. Bupropion 39-48 mitogen-activated protein kinase 8 Homo sapiens 151-154 21737767-3 2011 The purpose of the current study was to examine whether, in a controlled study, bupropion would improve the symptoms of RLS, or at least not exacerbate them. Bupropion 80-89 RLS1 Homo sapiens 120-123 21737767-10 2011 Bupropion was more effective than placebo in the treatment of RLS at 3 weeks; however, this difference was not statistically significant at 6 weeks. Bupropion 0-9 RLS1 Homo sapiens 62-65 21737767-11 2011 CONCLUSIONS: The data from our study suggest that bupropion does not exacerbate the symptoms of RLS and may be a reasonable choice if an antidepressant is needed in individuals with RLS. Bupropion 50-59 RLS1 Homo sapiens 182-185 21737767-12 2011 Larger studies that include titration of bupropion should be considered to determine if bupropion is appropriate for primary treatment of RLS, particularly considering the lower cost and favorable side effect profile compared with currently recommended first-line dopamine agonists. Bupropion 88-97 RLS1 Homo sapiens 138-141 20939765-6 2011 Additionally, the IC(50) values of bupropion, tolbutamide, and testosterone in inhibiting UGT-mediated metabolisms were similar with the K(m) values of respective CYPs. Bupropion 35-44 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 90-93 21216268-8 2011 Western blot analyses showed that bupropion significantly decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2), and this effect also was blocked by MEK inhibitor. Bupropion 34-43 mitogen activated protein kinase 3 Rattus norvegicus 104-149 21216268-8 2011 Western blot analyses showed that bupropion significantly decreased the 4-AP-induced phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2), and this effect also was blocked by MEK inhibitor. Bupropion 34-43 mitogen activated protein kinase 3 Rattus norvegicus 151-157 21216268-9 2011 These results are the first to suggest that, in rat cerebrocortical nerve terminals, bupropion suppresses voltage-dependent Ca(2+) channel and MEK/ERK activity and in so doing inhibits evoked glutamate release. Bupropion 85-94 Eph receptor B1 Rattus norvegicus 147-150 21121944-5 2011 The Phase I metabolism of the established marker drugs: midazolam, bupropion and dextromethorphan were measured by LC-MS and confirmed the activities of the 3A, 2B and 2D families of CYP isoforms, respectively. Bupropion 67-76 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 183-186 21266057-6 2011 Participants responded to survey items and provided blood samples for evaluation of phenotype and genotype of CYP2A6 and CYP2B6 enzymes involved in nicotine and bupropion metabolism. Bupropion 161-170 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 110-116 21266057-6 2011 Participants responded to survey items and provided blood samples for evaluation of phenotype and genotype of CYP2A6 and CYP2B6 enzymes involved in nicotine and bupropion metabolism. Bupropion 161-170 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 121-127 21372402-1 2011 Bupropion is an atypical antidepressant that is biotransformed in humans to its major active metabolite hydroxybupropion by cytochrome P450 2B6 (CYP2B6). Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 124-143 21372402-1 2011 Bupropion is an atypical antidepressant that is biotransformed in humans to its major active metabolite hydroxybupropion by cytochrome P450 2B6 (CYP2B6). Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 145-151 21372402-2 2011 Co-administration of bupropion with an inhibitor of CYP2B6 can result in a serious drug interaction, leading to bupropion related adverse effects (e.g. seizures). Bupropion 21-30 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 52-58 21372402-2 2011 Co-administration of bupropion with an inhibitor of CYP2B6 can result in a serious drug interaction, leading to bupropion related adverse effects (e.g. seizures). Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 52-58 21372402-12 2011 Our findings support future in vivo drug interaction studies in mice between bupropion and CYP2B6 inhibitors. Bupropion 77-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 91-97 20876786-0 2011 Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Bupropion 92-101 nuclear receptor subfamily 1 group I member 2 Homo sapiens 11-30 20876786-0 2011 Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Bupropion 92-101 nuclear receptor subfamily 1 group I member 2 Homo sapiens 32-37 20876786-0 2011 Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Bupropion 92-101 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 43-49 20876786-3 2011 The area under the time-concentration curve (AUC) ratio of hydroxybupropion to bupropion in CYP2B6*6 carriers was significantly lower than that in CYP2B6*6 noncarriers in both the basal and rifampin-induced states (p = 0.012). Bupropion 66-75 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 20876786-7 2011 In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers. Bupropion 68-77 nuclear receptor subfamily 1 group I member 2 Homo sapiens 35-40 20876786-7 2011 In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers. Bupropion 68-77 queuine tRNA-ribosyltransferase catalytic subunit 1 Homo sapiens 41-44 20876786-7 2011 In conclusion, it is suggested the NR1I2 TGT genotype decreases the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers. Bupropion 68-77 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 144-150 22249001-4 2011 In the majority of phase 3 trials, naltrexone/bupropion significantly improved proportion of patients achieving >=10% weight loss, waist circumference, triglycerides, high-density lipoprotein, fasting insulin, insulin resistance, and obesity-specific quality of life compared to placebo. Bupropion 46-55 insulin Homo sapiens 204-211 22249001-4 2011 In the majority of phase 3 trials, naltrexone/bupropion significantly improved proportion of patients achieving >=10% weight loss, waist circumference, triglycerides, high-density lipoprotein, fasting insulin, insulin resistance, and obesity-specific quality of life compared to placebo. Bupropion 46-55 insulin Homo sapiens 213-220 20880642-10 2010 Paroxetine, fluoxetine and bupropion are strong CYP2D6 inhibitors which should be avoided in tamoxifen users. Bupropion 27-36 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 20599802-6 2010 Bupropion was transported by BCRP (K(t) 3 microM, V(max) 30 pmol/mg protein/min) and P-gp (K(t) 0.5 microM, V(max) 6 pmol/mg protein min) in placental inside-out vesicles (IOVs). Bupropion 0-9 BCR pseudogene 1 Homo sapiens 29-33 20599802-6 2010 Bupropion was transported by BCRP (K(t) 3 microM, V(max) 30 pmol/mg protein/min) and P-gp (K(t) 0.5 microM, V(max) 6 pmol/mg protein min) in placental inside-out vesicles (IOVs). Bupropion 0-9 phosphoglycolate phosphatase Homo sapiens 85-89 20720111-10 2010 Most importantly, our studies highlighted that amphetamine, nomifensine, and bupropion, through increased striatal dopaminergic transmission, are able to revert motor hyperactivity of DAT-CI animals. Bupropion 77-86 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 184-187 20528624-0 2010 The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Bupropion 27-36 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 87-107 20528624-1 2010 The involvement of cytochrome P450 2B6 (CYP2B6) to the in vitro and in vivo metabolism of bupropion has been well studied. Bupropion 90-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 19-38 20528624-1 2010 The involvement of cytochrome P450 2B6 (CYP2B6) to the in vitro and in vivo metabolism of bupropion has been well studied. Bupropion 90-99 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 40-46 20528624-5 2010 CYP2C19 was involved in bupropion metabolism primarily through alternate hydroxylation pathways (M4-M6) with higher activity at lower substrate concentrations, near 1 microM. Bupropion 24-33 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 0-7 20528624-9 2010 In addition, the new findings revealed that CYP2C19 also contributes to bupropion metabolism through alternate hydroxylation pathways. Bupropion 72-81 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 44-51 20642555-4 2010 Bupropion undergoes metabolic transformation to the active metabolite, 4-hydroxybupropion, primarily via CYP2B6 both in vivo and in vitro. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 105-111 20642555-9 2010 AIMS: To examine the effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, formed via CYP2B6 in vivo. Bupropion 91-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 159-165 20382755-5 2010 Both dog CYP2A13 and CYP2A25 exhibited little or no catalytic activity toward other common cytochrome P450 probe substrates, including bupropion, amodiaquine, diclofenac, S-mephenytoin, bufuralol, dextromethorphan, midazolam, and testosterone. Bupropion 135-144 cytochrome P450 family 2 subfamily A polypeptide 13 Canis lupus familiaris 9-16 20382755-5 2010 Both dog CYP2A13 and CYP2A25 exhibited little or no catalytic activity toward other common cytochrome P450 probe substrates, including bupropion, amodiaquine, diclofenac, S-mephenytoin, bufuralol, dextromethorphan, midazolam, and testosterone. Bupropion 135-144 cytochrome P450, family 2, subfamily A, polypeptide 7 Canis lupus familiaris 21-28 20102294-1 2010 The objective of this study was to investigate the effects of continuous St. John"s wort administration on single-dose pharmacokinetics of bupropion, a substrate of cytochrome P450 (CYP) 2B6, in healthy Chinese volunteers. Bupropion 139-148 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 165-190 20004658-4 2010 Finally, the noradrenalin transporter together with dopamine transporter blocker bupropion was more effective in decreasing the stress of an injection in SERT(-/-) rats than in SERT(+/+) rats. Bupropion 81-90 solute carrier family 6 member 4 Rattus norvegicus 154-158 19969097-2 2010 Bupropion inhibits striatal dopamine reuptake via dopamine transporter blockade, but it is unknown whether this leads to increased extracellular dopamine levels at clinical doses in man. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 50-70 19969097-8 2010 Levels of dopamine transporter occupancy in the rat at 11 and 25 mg/kg bupropion i.p. Bupropion 71-80 solute carrier family 6 member 3 Homo sapiens 10-30 20208386-4 2010 Studies with HLM under-predict the ability of gemfibrozil and bupropion to cause clinically significant inhibition of CYP2C8 and CYP2D6, respectively, and over-predict the ability of ezetimibe to cause clinically significant inhibition of CYP3A4. Bupropion 62-71 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 118-124 20208386-4 2010 Studies with HLM under-predict the ability of gemfibrozil and bupropion to cause clinically significant inhibition of CYP2C8 and CYP2D6, respectively, and over-predict the ability of ezetimibe to cause clinically significant inhibition of CYP3A4. Bupropion 62-71 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 129-135 20208386-5 2010 Gemfibrozil and bupropion represent examples of glucuronidation-dependent and reduction-dependent activation to metabolites that inhibit CYP2C8 and CYP2D6, respectively, whereas ezetimibe represents an example of glucuronidation-dependent protection against metabolism-dependent inhibition of CYP3A4. Bupropion 16-25 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 137-143 20208386-5 2010 Gemfibrozil and bupropion represent examples of glucuronidation-dependent and reduction-dependent activation to metabolites that inhibit CYP2C8 and CYP2D6, respectively, whereas ezetimibe represents an example of glucuronidation-dependent protection against metabolism-dependent inhibition of CYP3A4. Bupropion 16-25 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 148-154 20046035-6 2009 Moreover, cynomolgus CYP2B6 revealed activities toward testosterone 16beta-hydroxylation and bupropion hydroxylation. Bupropion 93-102 cytochrome P450 family 2 subfamily B member 6 Macaca fascicularis 21-27 19928382-9 2009 At doses that produced equal increases in wake, DA-releasing (amphetamine, methamphetamine, phentermine) and several DAT-inhibiting agents (cocaine, bupropion, and methylphenidate) produced RHS during the first few hours after the onset of sleep recovery. Bupropion 149-158 solute carrier family 6 member 3 Rattus norvegicus 117-120 19631612-5 2009 Antidepressants, such as bupropion, also inhibit nicotinic receptor (nAChR) function. Bupropion 25-34 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 69-74 19464134-2 2009 Bupropion hydrochloride crystallizes as a racemate in monoclinic system, space group P2(1)/c with Z=4, a=14.3406(3)A, b=8.7564(2)A, c=11.8801(2)A, beta=78.025(2) degrees , V=1459.34(5)A(3). Bupropion 0-23 cyclin dependent kinase inhibitor 1A Homo sapiens 85-90 19702527-4 2009 CYP2B6 can metabolise approximately 8% of clinically used drugs (n > 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol. Bupropion 174-183 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 19702527-18 2009 Smokers with the 1459C>T (R487C) variant of CYP2B6 may be more vulnerable to abstinence symptoms and relapse following treatment with bupropion as a smoking cessation agent. Bupropion 137-146 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 19487249-0 2009 Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Bupropion 37-46 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 20-26 19487249-5 2009 Therefore, we investigated the effect of G. biloba extract and some of its chemical constituents (terpene trilactones and flavonols) on the in vitro catalytic activity of CYP2B6 as assessed by the bupropion hydroxylation assay with recombinant enzyme and hepatic microsomes. Bupropion 197-206 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 171-177 19487249-7 2009 Enzyme kinetic analysis indicated that G. biloba extract competitively inhibited hepatic microsomal CYP2B6-catalyzed bupropion hydroxylation (apparent K(i) was 162 +/- 14 microg/ml). Bupropion 117-126 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 100-106 19217624-2 2009 The objective of this study was to assess the early effect on adiponectin levels of smoking cessation supported by bupropion. Bupropion 115-124 adiponectin, C1Q and collagen domain containing Homo sapiens 62-73 19537999-3 2009 While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion. Bupropion 216-225 proopiomelanocortin Homo sapiens 185-205 19118567-6 2009 However, bupropion hydroxylation correlated well with Cyp2b1 expression in rat hepatocytes. Bupropion 9-18 cytochrome P450, family 2, subfamily b, polypeptide 1 Rattus norvegicus 54-60 19193596-1 2009 OBJECTIVE: To describe a case of restless legs syndrome (RLS) successfully managed with bupropion. Bupropion 88-97 RLS1 Homo sapiens 57-60 19193596-7 2009 Although not widely used for RLS, bupropion XL (Wellbutrin XL) 150 mg daily was initiated, resulting in resolution of RLS within 3 days. Bupropion 48-61 RLS1 Homo sapiens 118-121 19193596-11 2009 This case supports findings from other cases suggesting a beneficial response with bupropion for the management of RLS. Bupropion 83-92 RLS1 Homo sapiens 115-118 19193596-12 2009 CONCLUSION: Bupropion may be a treatment option for patients who have RLS and are unable to tolerate dopamine agonists. Bupropion 12-21 RLS1 Homo sapiens 70-73 19897080-5 2009 Regarding the interaction of BP with the DA transporter, residues S359, located in the middle of TM7, and A279, located close to the extracellular end of TM5, contribute to the binding and blockade of translocation mediated by BP, respectively. Bupropion 29-31 solute carrier family 6 member 3 Homo sapiens 41-55 19897080-5 2009 Regarding the interaction of BP with the DA transporter, residues S359, located in the middle of TM7, and A279, located close to the extracellular end of TM5, contribute to the binding and blockade of translocation mediated by BP, respectively. Bupropion 29-31 tropomyosin 3 Homo sapiens 154-157 19897080-5 2009 Regarding the interaction of BP with the DA transporter, residues S359, located in the middle of TM7, and A279, located close to the extracellular end of TM5, contribute to the binding and blockade of translocation mediated by BP, respectively. Bupropion 227-229 solute carrier family 6 member 3 Homo sapiens 41-55 19897080-5 2009 Regarding the interaction of BP with the DA transporter, residues S359, located in the middle of TM7, and A279, located close to the extracellular end of TM5, contribute to the binding and blockade of translocation mediated by BP, respectively. Bupropion 227-229 tropomyosin 3 Homo sapiens 154-157 18989234-0 2008 Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. Bupropion 51-60 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 18989234-1 2008 OBJECTIVE: To characterize the effect of efavirenz on bupropion hydroxylation as a marker of cytochrome P450 (CYP) 2B6 activity in healthy subjects. Bupropion 54-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-118 18989234-8 2008 The 2 individuals homozygous for multidrug resistance protein 1 3435-T/T had 2.5- and 1.8-fold greater bupropion and efavirenz clearance, respectively, relative to C/C and C/T individuals (P<0.05). Bupropion 103-112 ATP binding cassette subfamily B member 1 Homo sapiens 33-63 18989234-9 2008 CONCLUSIONS: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration. Bupropion 122-131 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 18930778-18 2008 Evidence from DP in intoxication with substances influencing the dopamine transporter (DAT) (e.g. cocaine, methylphenidate, bupropion) further supports this observation. Bupropion 124-133 solute carrier family 6 member 3 Homo sapiens 65-85 18930778-18 2008 Evidence from DP in intoxication with substances influencing the dopamine transporter (DAT) (e.g. cocaine, methylphenidate, bupropion) further supports this observation. Bupropion 124-133 solute carrier family 6 member 3 Homo sapiens 87-90 18708076-11 2008 These results indicate that bupropion, unlike 5-HT reuptake inhibitors, promptly increased 5-HT neuronal activity, due to early desensitization of the 5-HT1A autoreceptor. Bupropion 28-37 5-hydroxytryptamine receptor 1A Rattus norvegicus 151-157 18442345-4 2008 RESULTS: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). Bupropion 62-74 CXADR pseudogene 1 Homo sapiens 9-12 18706108-10 2008 The convulsive dose of bupropion HCl required to induce seizures in 50% of mice (CD50), was 116.72 mg/kg for bupropion HCl alone (CI: 107.95, 126.20) and 89.40 mg/kg for ethanol/bupropion HCl (CI: 64.92, 123.10). Bupropion 23-36 intercellular adhesion molecule 5, telencephalin Mus musculus 81-85 18474675-3 2008 In addition, the formations of M1 from sibutramine (r = 0.694, p = 0.0029) and M2 from M1 (r = 0.834, p < 0.0001) were strongly correlated with CYP2B6-catalyzed bupropion hydroxylation in 16 different HLM panels. Bupropion 164-173 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 147-153 18705749-9 2008 ), a novel sigma-1 receptor antagonist, reversed the anti-immobility effects of bupropion (20 mg/kg, i.p.). Bupropion 80-89 sigma non-opioid intracellular receptor 1 Mus musculus 11-27 18778441-10 2008 CONCLUSIONS: Chronic nicotine infusion reduces the synthesis of 5HTT protein, which may consequently precipitate depression during nicotine withdrawal, but co-administration of bupropion may ameliorate withdrawal symptoms by counteracting nicotine"s effect on 5HTT. Bupropion 177-186 solute carrier family 6 member 4 Rattus norvegicus 260-264 18625984-12 2008 In our analysis of data from the varenicline trials that included bupropion control arms, we found that varenicline was superior to bupropion (OR 2.18, 95% CrI 1.09-4.08). Bupropion 132-141 EP300 interacting inhibitor of differentiation 1 Homo sapiens 156-161 18691982-13 2008 Duloxetine and bupropion are moderate inhibitors of CYP2D6, and sertraline may cause significant inhibition of this isoform, but only at high doses. Bupropion 15-24 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 52-58 18420781-1 2008 There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure. Bupropion 61-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 79-85 18420781-4 2008 In human liver microsomes using the CYP2D6 probe substrate bufuralol, erythrohydrobupropion and threohydrobupropion were more potent inhibitors of CYP2D6 activity (K(i) = 1.7 and 5.4 microM, respectively) than hydroxybupropion (K(i) = 13 microM) or bupropion (K(i) = 21 microM). Bupropion 82-91 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 36-42 18420781-4 2008 In human liver microsomes using the CYP2D6 probe substrate bufuralol, erythrohydrobupropion and threohydrobupropion were more potent inhibitors of CYP2D6 activity (K(i) = 1.7 and 5.4 microM, respectively) than hydroxybupropion (K(i) = 13 microM) or bupropion (K(i) = 21 microM). Bupropion 82-91 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 147-153 18420781-7 2008 This work indicates that the reductive metabolites of bupropion are potent competitive CYP2D6 inhibitors in vivo and provides a mechanistic explanation for the clinical drug-drug interaction between bupropion and desipramine. Bupropion 54-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 18420781-7 2008 This work indicates that the reductive metabolites of bupropion are potent competitive CYP2D6 inhibitors in vivo and provides a mechanistic explanation for the clinical drug-drug interaction between bupropion and desipramine. Bupropion 199-208 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 18484717-6 2008 3H2O, t-BuP(O)(OH)2, 3,5-dimethylpyrazole, and triethylamine afforded another dodecanuclear cage [Cu12(mu-DMPz)8(eta1-DMPzH)2(mu4-O)2(mu3-OH)4(mu3- t-BuPO3)4].3MeOH (3). Bupropion 8-11 secreted phosphoprotein 1 Homo sapiens 113-117 18332082-4 2008 To identify individual constituents with inhibitory activity, the suspension was partitioned using hexane, ethyl acetate, and dichloromethane, and each fraction was tested for its inhibitory effect on CYP2B6-catalyzed bupropion hydroxylation. Bupropion 218-227 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 201-207 18219560-0 2008 Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Bupropion 30-39 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 18219560-2 2008 Bupropion hydroxylation is catalyzed selectively by cytochrome P4502B6 (CYP2B6). Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 18219560-3 2008 CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion 17-26 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 18219560-3 2008 CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion 17-26 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 18219560-3 2008 CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion 17-26 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 103-109 18219560-5 2008 Nevertheless, it is unknown whether CYP2B6-catalyzed bupropion hydroxylation is stereoselective. Bupropion 53-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 36-42 18219560-6 2008 METHODS: Hydroxylation of racemic bupropion by recombinant CYP2B6 and human liver microsomes was evaluated using a stereoselective assay. Bupropion 34-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 59-65 18219560-7 2008 RESULTS: At therapeutic concentrations, hydroxylation of (S)-bupropion was threefold and 1.5-greater than (R)-bupropion, respectively, by recombinant CYP2B6 and human liver microsomes. Bupropion 57-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 150-156 18219560-9 2008 CONCLUSIONS: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity. Bupropion 29-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 232-238 18285471-7 2008 Stereoselective bupropion hydroxylation was used as an in vivo probe for CYP2B6 activity. Bupropion 16-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 73-79 18287571-0 2008 Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. Bupropion 16-25 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 95-101 18287571-1 2008 The clearance of racemic bupropion, metabolized selectively by CYP2B6 in vitro, has been used clinically to phenotype CYP2B6 activity, polymorphisms, and drug interactions but has known limitations. Bupropion 25-34 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 18287571-1 2008 The clearance of racemic bupropion, metabolized selectively by CYP2B6 in vitro, has been used clinically to phenotype CYP2B6 activity, polymorphisms, and drug interactions but has known limitations. Bupropion 25-34 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 118-124 18287571-2 2008 Bupropion hydroxylation by CYP2B6 is stereoselective. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 18171905-1 2008 CYP2B6 is a polymorphic human drug metabolizing cytochrome P450 with clinical relevance for several drug substrates including cyclophosphamide, bupropion, and efavirenz. Bupropion 144-153 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 18239278-2 2008 In the present study, the transport activity of P-gp for sertraline, desmethylsertraline, bupropion, and the major metabolites of bupropion, threo-amino alcohol (TB), erythro-amino alcohol (EB), and hydroxy metabolite (HB) was studied using an ATPase assay in expressed human P-gp membranes by measuring concentrations of inorganic P(i) in expressed human P-gp membranes. Bupropion 90-99 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 18239278-2 2008 In the present study, the transport activity of P-gp for sertraline, desmethylsertraline, bupropion, and the major metabolites of bupropion, threo-amino alcohol (TB), erythro-amino alcohol (EB), and hydroxy metabolite (HB) was studied using an ATPase assay in expressed human P-gp membranes by measuring concentrations of inorganic P(i) in expressed human P-gp membranes. Bupropion 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 18239278-2 2008 In the present study, the transport activity of P-gp for sertraline, desmethylsertraline, bupropion, and the major metabolites of bupropion, threo-amino alcohol (TB), erythro-amino alcohol (EB), and hydroxy metabolite (HB) was studied using an ATPase assay in expressed human P-gp membranes by measuring concentrations of inorganic P(i) in expressed human P-gp membranes. Bupropion 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 276-280 18239278-2 2008 In the present study, the transport activity of P-gp for sertraline, desmethylsertraline, bupropion, and the major metabolites of bupropion, threo-amino alcohol (TB), erythro-amino alcohol (EB), and hydroxy metabolite (HB) was studied using an ATPase assay in expressed human P-gp membranes by measuring concentrations of inorganic P(i) in expressed human P-gp membranes. Bupropion 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 276-280 18239278-7 2008 Bupropion and its three metabolites showed very weak affinity for P-gp, with V(max)/K(m) values lower than 0.01 min(-1) x 10(-3). Bupropion 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 18239278-8 2008 The results of the present study indicate that sertraline and desmethylsertraline have high affinity for P-gp, whereas bupropion and its three major metabolites TB, EB, and HB have very weak affinity for P-gp. Bupropion 119-128 ATP binding cassette subfamily B member 1 Homo sapiens 204-208 18197080-4 2008 METHODS: Six candidate genes, thought to be involved in the interaction of nicotine and bupropion (for example, the dopamine receptor type 2, dopamine transporter, norepinephrine transporter, serotonin transporter, catecholamine-O-methyltransferase), and the clinical outcomes of smoking behavior were investigated. Bupropion 88-97 solute carrier family 6 member 2 Homo sapiens 164-190 18094219-6 2008 Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmax and AUC0-infinity by 14% and 18%, respectively, and decreased hydroxybupropion Cmax and AUC0-infinity by 32% and 23%. Bupropion 59-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 223-232 interferon gamma Homo sapiens 4-13 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 223-232 indoleamine 2,3-dioxygenase 1 Homo sapiens 14-17 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 223-232 nitric oxide synthase 2 Homo sapiens 18-22 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 234-244 interferon gamma Homo sapiens 4-13 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 234-244 indoleamine 2,3-dioxygenase 1 Homo sapiens 14-17 18077563-11 2007 The IFN-gamma-IDO-iNOS hypothesis of VCI suggests new ways of preventing (identifying population at risk by analysis of IFN-gamma and TNF-alpha genetic polymorphism) and treating VCI (using IDO inhibitors and melatonin and bupropion [Wellbutrin] as agents suppressing IFN-gamma and TNF-alpha production). Bupropion 234-244 nitric oxide synthase 2 Homo sapiens 18-22 18058343-0 2007 Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Bupropion 0-9 dopamine receptor D2 Homo sapiens 62-66 18058343-6 2007 These data suggest that bupropion may be effective for smoking cessation only in a subgroup of smokers with the DRD2 Taq1 A2/A2 genotype. Bupropion 24-33 dopamine receptor D2 Homo sapiens 112-116 17709370-5 2007 Acetonitrile, DMSO, and ethanol were shown to increase the Km and decrease the intrinsic clearance (CLint) of CYP2B6-mediated bupropion hydroxylation in a concentration-dependent manner. Bupropion 126-135 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 110-116 17223085-0 2007 CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Bupropion 45-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 17223085-1 2007 BACKGROUND: CYP2B6 is the primary enzyme involved in bupropion (Zyban; GlaxoSmithKline, Research Triangle Park, North Carolina) metabolism. Bupropion 53-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 17223085-1 2007 BACKGROUND: CYP2B6 is the primary enzyme involved in bupropion (Zyban; GlaxoSmithKline, Research Triangle Park, North Carolina) metabolism. Bupropion 64-69 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 17223085-2 2007 Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome. Bupropion 61-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 25-31 17223085-2 2007 Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome. Bupropion 61-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-47 17223085-2 2007 Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome. Bupropion 97-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 25-31 17223085-2 2007 Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome. Bupropion 97-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-47 17223085-9 2007 CONCLUSIONS: These data suggest that smokers with the CYP2B6*6 genotype have a higher liability to relapse on placebo and that they may be good candidates for bupropion treatment for smoking cessation. Bupropion 159-168 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 54-60 17697034-0 2007 Is bupropion a more specific substrate for porcine CYP2E than chlorzoxazone and p-nitrophenol? Bupropion 3-12 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 51-56 17697034-5 2007 Incubation with bupropion concentrations ranging from 0.05 to 20 mM and with various inhibitors revealed that this substrate is metabolized by both CYP2A and CYP2E. Bupropion 16-25 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 148-153 17697034-5 2007 Incubation with bupropion concentrations ranging from 0.05 to 20 mM and with various inhibitors revealed that this substrate is metabolized by both CYP2A and CYP2E. Bupropion 16-25 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 158-163 17697034-9 2007 Furthermore, bupropion is a more specific substrate for CYP2E than chlorzoxazone and p-nitrophenol although not perfect. Bupropion 13-22 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 56-61 17335546-1 2007 AIMS: To investigate the effect of kidney disease on bupropion pharmacokinetics and on cytochrome P450 (CYP) 2B6 activity as measured by bupropion hydroxylation. Bupropion 137-146 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-112 17654295-8 2007 Although these results require replication, the data suggest preliminarily that the DRD2-Taq1A polymorphism may influence treatment response to bupropion for smoking cessation and, further, that exploration of gene x gene and gene x craving interactions in future, larger studies may provide mechanistic insights into the complex pharmacodynamics of bupropion. Bupropion 144-153 dopamine receptor D2 Homo sapiens 84-88 17509558-19 2007 [a specific neuronal nitric oxide synthase (nNOS) inhibitor] produced potentiation of the action of subeffective dose of bupropion (10 mg/kg i.p.). Bupropion 121-130 nitric oxide synthase 1, neuronal Mus musculus 12-42 17509558-19 2007 [a specific neuronal nitric oxide synthase (nNOS) inhibitor] produced potentiation of the action of subeffective dose of bupropion (10 mg/kg i.p.). Bupropion 121-130 nitric oxide synthase 1, neuronal Mus musculus 44-48 17509558-21 2007 [direct inhibitor of both nitric oxide synthase (NOS) and soluble guanylate cyclase (sGC)] potentiated the effect of bupropion (10 mg/kg., i.p.) Bupropion 117-126 nitric oxide synthase 1, neuronal Mus musculus 26-47 17529897-0 2007 Bupropion interference with immunoassays for amphetamines and LSD. Bupropion 0-9 deoxyribonuclease 1 like 3 Homo sapiens 62-65 17529897-5 2007 Using gas chromatography/mass spectrometry (GC/MS), and liquid chromatography/mass spectrometry (LC/MS), the authors identified bupropion, a drug used to aid in smoking cessation, as the interfering compound, which may cause false-positive results for amphetamines and LSD using the CEDIA assays. Bupropion 128-137 deoxyribonuclease 1 like 3 Homo sapiens 269-272 17500623-2 2007 DESIGN: Three hundred twenty-three participants in a bupropion SR smoking cessation effectiveness trial with 12-month follow-up were genotyped for variants of dopamine receptor gene DRD2 and dopamine transporter SLC6A3. Bupropion 53-62 dopamine receptor D2 Homo sapiens 182-186 17500623-2 2007 DESIGN: Three hundred twenty-three participants in a bupropion SR smoking cessation effectiveness trial with 12-month follow-up were genotyped for variants of dopamine receptor gene DRD2 and dopamine transporter SLC6A3. Bupropion 53-62 solute carrier family 6 member 3 Homo sapiens 212-218 17142561-4 2007 Bupropion hydroxylation, amodiaquine N-deethylation, and midazolam 1"-hydroxylation were chosen as probe reactions for CYP2B6, CYP2C8, and CYP3A5 and were analyzed using liquid chromatography-tandem mass spectrometry. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 119-125 16876132-0 2007 Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Bupropion 70-79 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 0-28 16876132-0 2007 Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Bupropion 70-79 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 30-34 16876132-3 2007 We investigated variants in the catechol-O-methyltransferase (COMT) gene in a smoking cessation trial of bupropion. Bupropion 105-114 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 32-60 16876132-3 2007 We investigated variants in the catechol-O-methyltransferase (COMT) gene in a smoking cessation trial of bupropion. Bupropion 105-114 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 62-66 16876132-6 2007 RESULTS: At the end of the treatment phase, statistically significant interaction effects indicated that COMT haplotypes of two SNPs (rs737865 and rs165599) predicted the efficacy of bupropion compared with placebo. Bupropion 183-192 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 105-109 16876132-8 2007 CONCLUSIONS: COMT haplotypes at rs737865 and rs165599 may predict a favorable outcome for bupropion treatment for smoking cessation. Bupropion 90-99 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 13-17 16876132-11 2007 If study findings are confirmed in additional large studies, COMT genotyping could be applied to identify likely responders to bupropion treatment for smoking cessation. Bupropion 127-136 caffeic acid 3-O-methyltransferase-like Nicotiana tabacum 61-65 17082249-1 2007 BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz. Bupropion 181-190 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 12-18 17082249-1 2007 BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz. Bupropion 181-190 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 56-71 17082249-1 2007 BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz. Bupropion 181-190 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 12-15 17189751-9 2007 Bupropion could potentially "correct" dopaminergic dysfunction in RLS, and sertraline appears to be the SSRI that provides the least risk of RLS by blocking dopamine reuptake. Bupropion 0-9 RLS1 Homo sapiens 66-69 17498391-1 2007 PURPOSE: The purpose of this study was to quantify the intestinal metabolism of midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform CYP3A4/1 and to compare it with previous results obtained for other P450 substrates such as testosterone, dextromethorphan and bupropion, which show some specificities for different CYP isoforms. Bupropion 296-305 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 169-177 17498391-1 2007 PURPOSE: The purpose of this study was to quantify the intestinal metabolism of midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform CYP3A4/1 and to compare it with previous results obtained for other P450 substrates such as testosterone, dextromethorphan and bupropion, which show some specificities for different CYP isoforms. Bupropion 296-305 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 169-172 17264803-1 2007 OBJECTIVES: To examine the association between polymorphisms in the dopamine transporter gene (SLC6A3, DAT1) and treatment outcome in smokers attempting to quit using either nicotine replacement therapy or bupropion. Bupropion 206-215 solute carrier family 6 member 3 Homo sapiens 68-88 17264803-1 2007 OBJECTIVES: To examine the association between polymorphisms in the dopamine transporter gene (SLC6A3, DAT1) and treatment outcome in smokers attempting to quit using either nicotine replacement therapy or bupropion. Bupropion 206-215 solute carrier family 6 member 3 Homo sapiens 95-101 17101742-1 2006 Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion, efavirenz, propofol, and selegiline, among others. Bupropion 76-85 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-19 17101742-1 2006 Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion, efavirenz, propofol, and selegiline, among others. Bupropion 76-85 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 16893531-5 2006 The exception was bupropion, a dual norepinephrine transporter/dopamine transporter blocker, which tended to increase spontaneous locomotor activity. Bupropion 18-27 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 Mus musculus 36-62 16893531-7 2006 Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in norepinephrine transporter knockout mice. Bupropion 110-119 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 Mus musculus 0-26 16949560-10 2006 Taken together these results demonstrate that when administered in the presence of nicotine, bupropion elicits unique pharmacological differences such that it exhibits both nAChR agonist- and antagonistic-like effects. Bupropion 93-102 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 173-178 17073575-2 2006 For bupropion, cyclophosphamide, ifosfamide, pethidine, ketamine and propofol, these reactions represent major metabolic or activation pathways and for their kinetics CYP2B6 function is of considerable importance. Bupropion 4-13 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 167-173 17073575-6 2006 Bupropion hydroxylation is a selective, and consequently useful, in vivo probe for CYP2B6. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 83-89 17073575-8 2006 With validated in vitro and in vivo substrates (e.g. bupropion) and inhibitors (e.g. ticlopidine), it is expected that pharmacological (including pharmacogenetic) and clinical significance of CYP2B6 will be delineated more fully in the near future. Bupropion 53-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 192-198 17136226-4 2006 In addition to proven clinical efficacy for the treatment of major depression, the prevention of depressive episodes in patients with seasonal affective disorder, and as an aid to smoking cessation treatment, bupropion has demonstrated efficacy for attenuation of symptoms of attention deficit hyperactivity disorder, and more recently it has shown anti-inflammatory action against proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), which may be implicated in a number of inflammatory diseases such as Crohn"s disease. Bupropion 209-218 tumor necrosis factor Homo sapiens 416-443 17136226-4 2006 In addition to proven clinical efficacy for the treatment of major depression, the prevention of depressive episodes in patients with seasonal affective disorder, and as an aid to smoking cessation treatment, bupropion has demonstrated efficacy for attenuation of symptoms of attention deficit hyperactivity disorder, and more recently it has shown anti-inflammatory action against proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), which may be implicated in a number of inflammatory diseases such as Crohn"s disease. Bupropion 209-218 tumor necrosis factor Homo sapiens 445-454 17009913-2 2006 Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 106-125 17009913-2 2006 Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 127-133 17009913-2 2006 Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 165-184 17009913-2 2006 Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybupropion, through hepatic cytochrome P450-2B6 (CYP2B6) and has inhibitory effects on cytochrome P450-2D6 (CYP2D6), thus raising concern for clinically-relevant drug interactions. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 186-192 17009913-12 2006 Anecdotal reports indicate bupropion may lower inflammatory mediators such as tumor necrosis factor-alpha, may lower fatigue in cancer and may help reduce concentration problems. Bupropion 27-36 tumor necrosis factor Homo sapiens 78-105 16923164-2 2006 Taking advantage of the differential sensitivity of the dopamine and the norepinephrine transporters (DAT and NET) to benztropine and bupropion, we have used site-directed mutagenesis to produce gain-of-function mutants in NET which demonstrate that Ala279 in the trans-membrane domain 5 (TM5) and Ser359 in the TM7 of DAT are responsible for the higher sensitivity of DAT to both bupropion and benztropine. Bupropion 134-143 solute carrier family 6 member 3 Homo sapiens 102-105 16923164-2 2006 Taking advantage of the differential sensitivity of the dopamine and the norepinephrine transporters (DAT and NET) to benztropine and bupropion, we have used site-directed mutagenesis to produce gain-of-function mutants in NET which demonstrate that Ala279 in the trans-membrane domain 5 (TM5) and Ser359 in the TM7 of DAT are responsible for the higher sensitivity of DAT to both bupropion and benztropine. Bupropion 381-390 solute carrier family 6 member 3 Homo sapiens 102-105 16923164-5 2006 Thus, these studies begin to identify residues that are important for the unique molecular interactions of benztropine and bupropion with the DAT, and that ultimately may contribute to the distinct behavioral actions of these drugs. Bupropion 123-132 solute carrier family 6 member 3 Homo sapiens 142-145 16581944-5 2006 Correlation analysis between the known P450 enzyme activities and the rate of the formation of endosulfan sulfate in the 14 human liver microsomes showed that alpha-endosulfan metabolism is significantly correlated with CYP2B6-mediated bupropion hydroxylation and CYP3A-mediated midazolam hydroxylation, and that beta-endosulfan metabolism is correlated with CYP3A activity. Bupropion 236-245 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 220-226 16644475-0 2006 A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Bupropion 72-81 tumor necrosis factor Mus musculus 103-130 16644475-0 2006 A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Bupropion 72-81 interferon gamma Mus musculus 135-151 16644475-2 2006 We show here that a commonly used generic antidepressant bupropion, in wide use worldwide to treat depression in humans for a decade now, profoundly lowers levels of TNF, interferon-gamma, and interleukin-1 beta in vivo, in a mouse lipopolysaccharide (LPS) induced inflammation model. Bupropion 57-66 tumor necrosis factor Homo sapiens 166-169 16644475-2 2006 We show here that a commonly used generic antidepressant bupropion, in wide use worldwide to treat depression in humans for a decade now, profoundly lowers levels of TNF, interferon-gamma, and interleukin-1 beta in vivo, in a mouse lipopolysaccharide (LPS) induced inflammation model. Bupropion 57-66 interferon gamma Homo sapiens 171-187 16644475-2 2006 We show here that a commonly used generic antidepressant bupropion, in wide use worldwide to treat depression in humans for a decade now, profoundly lowers levels of TNF, interferon-gamma, and interleukin-1 beta in vivo, in a mouse lipopolysaccharide (LPS) induced inflammation model. Bupropion 57-66 interleukin 1 beta Homo sapiens 193-211 16644475-5 2006 Concordant with this, TNF suppression by bupropion in our mouse LPS model was largely abrogated by beta-adrenergic or dopamine D1 receptor antagonists but not by a D2 antagonist. Bupropion 41-50 tumor necrosis factor Mus musculus 22-25 16644475-7 2006 We conclude that bupropion may suppress TNF synthesis by mediating increased signaling at beta-adrenoreceptors and D1 receptors, resulting in increased cAMP that inhibits TNF synthesis. Bupropion 17-26 tumor necrosis factor Mus musculus 40-43 16644475-7 2006 We conclude that bupropion may suppress TNF synthesis by mediating increased signaling at beta-adrenoreceptors and D1 receptors, resulting in increased cAMP that inhibits TNF synthesis. Bupropion 17-26 tumor necrosis factor Mus musculus 171-174 16675366-12 2006 The atypical (i.e., alone in their class) antidepressants bupropion and mirtazapine are prolactin neutral. Bupropion 58-67 prolactin Homo sapiens 88-97 16309716-1 2006 CYP2B6 is a drug-metabolizing enzyme expressed in human tissues that can activate bupropion (a smoking cessation drug) and tobacco smoke nitrosamines and can inactivate drugs such as nicotine. Bupropion 82-91 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Bupropion 187-196 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 15-21 16309716-10 2006 In conclusion, CYP2B6 protein is expressed in specific cells in monkey brain and is induced by chronic nicotine treatment which may impact central metabolism of CYP2B6 substrates such as bupropion and nicotine. Bupropion 187-196 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 161-167 16091300-6 2006 Thus, the present study examined whether repeated treatment with antidepressant drugs that block the uptake of DA (nomifensine and bupropion) would modify [3H]-GBR12935 binding to DAT sites in WKY rats compared to WIS and S-D rats. Bupropion 131-140 solute carrier family 6 member 3 Rattus norvegicus 180-183 16091300-7 2006 The results indicate that while nomifensine and bupropion increased the binding of [3H]-GBR12935 to DAT sites in the mesocorticolimbic regions in WKY rats, these drugs increased the binding of [3H]-GBR12935 to DAT sites in the cell body areas in WIS rats but not in S-D and WKY rats. Bupropion 48-57 solute carrier family 6 member 3 Rattus norvegicus 100-103 16091300-7 2006 The results indicate that while nomifensine and bupropion increased the binding of [3H]-GBR12935 to DAT sites in the mesocorticolimbic regions in WKY rats, these drugs increased the binding of [3H]-GBR12935 to DAT sites in the cell body areas in WIS rats but not in S-D and WKY rats. Bupropion 48-57 solute carrier family 6 member 3 Rattus norvegicus 210-213 16246642-3 2005 Bupropion is used as a probe for the activity of the CYP2B6 isoenzyme of the P450 family of enzymes in man. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-59 16213028-0 2005 Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. Bupropion 60-69 solute carrier family 6 member 3 Homo sapiens 0-20 16213028-1 2005 BACKGROUND: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). Bupropion 12-21 solute carrier family 6 member 3 Homo sapiens 84-104 16213028-1 2005 BACKGROUND: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). Bupropion 12-21 solute carrier family 6 member 3 Homo sapiens 106-109 16213028-2 2005 The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc-TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. Bupropion 145-154 solute carrier family 6 member 3 Homo sapiens 46-49 16213028-7 2005 The average DAT occupancy due to the bupropion treatment was 20.84+/-27.7%. Bupropion 37-46 solute carrier family 6 member 3 Homo sapiens 12-15 16213028-10 2005 CONCLUSIONS: In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. Bupropion 92-101 solute carrier family 6 member 3 Homo sapiens 71-74 15964626-14 2005 Early data indicates that the common generic antidepressant bupropion may ameliorate Crohn"s disease course by down regulating TNF synthesis, maybe it will slow the course of MM as well. Bupropion 60-69 tumor necrosis factor Homo sapiens 127-130 16340389-4 2005 The authors report that a low dose of bupropion rapidly and completely ameliorated RLS symptoms in 3 depressed patients within a few days of the initiation of treatment. Bupropion 38-47 RLS1 Homo sapiens 83-86 16340389-5 2005 To their knowledge, this is the first report to show that bupropion may be an effective alternative for treating RLS. Bupropion 58-67 RLS1 Homo sapiens 113-116 16340389-6 2005 Consequently, bupropion may be useful for the treatment of patients with both depression and RLS. Bupropion 14-23 RLS1 Homo sapiens 93-96 16368442-3 2005 Bupropion hydrochloride, a noradrenergic/dopaminergic antidepressant, is available in 3 oral formulations: immediate release (IR) (given TID), sustained release (SR) (given BID), and extended release (XL) (given QD). Bupropion 0-23 BH3 interacting domain death agonist Homo sapiens 173-176 16368442-19 2005 In addition, bupropion inhibits CYP2D6 and may reduce clearance of agents metabolized by this enzyme. Bupropion 13-22 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 16005476-4 2005 The purpose of this study was to determine if other DAT inhibitors, including bupropion, similarly affect VMAT-2. Bupropion 78-87 solute carrier family 18 member A2 Homo sapiens 106-112 16005476-5 2005 Results revealed bupropion rapidly, reversibly, and dose-dependently increased vesicular DA uptake; an effect also associated with VMAT-2 protein redistribution. Bupropion 17-26 solute carrier family 18 member A2 Homo sapiens 131-137 16005476-8 2005 Although bupropion attenuated the METH-induced reduction in VMAT-2 activity acutely, it did not prevent the long-term dopaminergic toxicity or the METH-induced redistribution of VMAT-2 protein. Bupropion 9-18 solute carrier family 18 member A2 Homo sapiens 60-66 16220339-6 2005 Chronic bupropion and desipramine significantly decreased BDNF expression in the dentate gyrus of the hippocampus, while fluoxetine had no effect in any brain region. Bupropion 8-17 brain-derived neurotrophic factor Rattus norvegicus 58-62 16085363-7 2005 Results showed a decrease in catalase activity of the PFC and ST after SE and death induced by cocaine and bupropion overdoses. Bupropion 107-116 catalase Mus musculus 29-37 16011913-2 2005 As it is metabolised to hydroxybupropion specifically by CYP2B6, bupropion has also been used as a probe to assess CYP2B6 activity. Bupropion 31-40 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 57-63 16011913-9 2005 This assay is more sensitive than currently published methods using HPLC with UV detection for the simultaneous quantitation of bupropion and metabolites and can be used for assessing CYP2B6 activity in vivo following a single dose of bupropion. Bupropion 128-137 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 184-190 16011913-9 2005 This assay is more sensitive than currently published methods using HPLC with UV detection for the simultaneous quantitation of bupropion and metabolites and can be used for assessing CYP2B6 activity in vivo following a single dose of bupropion. Bupropion 235-244 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 184-190 15961986-0 2005 Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Bupropion 85-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 41-60 15961986-1 2005 OBJECTIVE: Our objective was to study the effect of the antiplatelet agents clopidogrel and ticlopidine on bupropion (INN, amfebutamone) hydroxylation, a probe reaction for cytochrome P450 (CYP) 2B6 activity. Bupropion 107-116 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 173-198 15961986-8 2005 CONCLUSIONS: Both clopidogrel and ticlopidine significantly inhibited the CYP2B6-catalyzed bupropion hydroxylation. Bupropion 91-100 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-80 15769884-1 2005 The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz. Bupropion 140-149 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 22-48 15876900-0 2005 Inhibition of CYP2D6 activity by bupropion. Bupropion 33-42 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 14-20 15876900-1 2005 The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Bupropion 54-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 67-86 15876900-1 2005 The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Bupropion 54-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 88-94 15876900-8 2005 At baseline, all subjects were phenotypically extensive CYP2D6 metabolizers (metabolic ratio <0.3); after treatment, 6 of 13 subjects receiving bupropion, but none of those receiving placebo, had metabolic ratios consistent with poor CYP2D6 metabolizers. Bupropion 147-156 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 237-243 15876900-9 2005 Bupropion is therefore a potent inhibitor of CYP2D6 activity, and care should be exercised when initiating or discontinuing bupropion use in patients taking drugs metabolized by CYP2D6. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-51 15876900-9 2005 Bupropion is therefore a potent inhibitor of CYP2D6 activity, and care should be exercised when initiating or discontinuing bupropion use in patients taking drugs metabolized by CYP2D6. Bupropion 0-9 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 178-184 15876900-9 2005 Bupropion is therefore a potent inhibitor of CYP2D6 activity, and care should be exercised when initiating or discontinuing bupropion use in patients taking drugs metabolized by CYP2D6. Bupropion 124-133 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 178-184 15647329-1 2005 To identify the brain nicotinic acetylcholine receptor (nAChR) subtypes that may be involved in nicotine addiction, we investigated the actions of bupropion, a drug used in cigarette smoking cessation programs, and nicotine on three pharmacologically identified nAChRs in rat hippocampal slices, namely, type IA, type II, and type III nAChRs, likely representing alpha7, alpha4beta2, and alpha3beta4 subunits, respectively. Bupropion 147-156 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 56-61 15647329-7 2005 Bupropion at 1 muM produced 56, 15, and 0% inhibition of type III, type II, and type IA nAChR responses, respectively, in the slices. Bupropion 0-9 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 88-93 15928583-0 2005 Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn"s disease and the therapeutic potential of bupropion to lower TNF-alpha. Bupropion 132-141 tumor necrosis factor Homo sapiens 27-36 15928583-0 2005 Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn"s disease and the therapeutic potential of bupropion to lower TNF-alpha. Bupropion 132-141 tumor necrosis factor Homo sapiens 151-160 15928583-4 2005 Bupropion is a commonly used generic antidepressant in clinical use for over a decade, and early evidence indicates it lowers TNF levels. Bupropion 0-9 tumor necrosis factor Homo sapiens 126-129 15928583-5 2005 This paper suggests the use of bupropion in CLL to lower TNF levels, which may thereby slow CLL disease course. Bupropion 31-40 tumor necrosis factor Homo sapiens 57-60 15866510-4 2005 administered bupropion in the CD97 dose (139.5 mg/kg). Bupropion 13-22 adhesion G protein-coupled receptor E5 Mus musculus 30-34 15652242-4 2005 Using human liver microsomes and recombinant P450 enzymes we confirmed potent inhibition of CYP2B6 enzyme activity determined with bupropion as substrate. Bupropion 131-140 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 15922115-0 2005 Proposal for using small molecule tumor necrosis factor-alpha lowering agents, possibly bupropion, in aplastic anemia. Bupropion 88-97 tumor necrosis factor Homo sapiens 34-61 15922115-4 2005 In preliminary studies we have found that the commonly used antidepressant bupropion lowers TNF. Bupropion 75-84 tumor necrosis factor Homo sapiens 92-95 15922115-5 2005 Thus, bupropion is a potential initial small molecule TNF inhibitor to consider for AA. Bupropion 6-15 tumor necrosis factor Homo sapiens 54-57 15533626-0 2005 Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis. Bupropion 0-9 tumor necrosis factor Homo sapiens 31-58 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 dihydrolipoamide S-acetyltransferase Homo sapiens 142-145 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 dihydrolipoamide S-acetyltransferase Homo sapiens 276-279 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 tumor necrosis factor Homo sapiens 285-312 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 tumor necrosis factor Homo sapiens 314-317 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 tumor necrosis factor Homo sapiens 338-341 15533626-5 2005 Here, we suggest that for a number of reasons that the safe and commonly used oral antidepressant bupropion might be effective for fatigue in PBC: (1) increased monoaminergic and dopaminergic tone to combat fatigue, (2) treatment of concomitant depression, (3) in general for PBC as a tumor necrosis factor-alpha (TNF) lowering agent, if TNF is eventually found to play a role in PBC pathogenesis. Bupropion 98-107 dihydrolipoamide S-acetyltransferase Homo sapiens 276-279 15492764-0 2005 Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Bupropion 87-99 dopamine receptor D2 Homo sapiens 18-22 15492764-2 2005 In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling. Bupropion 229-241 dopamine receptor D2 Homo sapiens 121-125 15541423-4 2004 Anti-immobility effects of bupropion and nomifensine were inhibited by the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-HCl (SCH 23390) and the dopamine D2 receptor antagonist sulpiride. Bupropion 27-36 dopamine receptor D1 Mus musculus 75-95 15541423-4 2004 Anti-immobility effects of bupropion and nomifensine were inhibited by the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-HCl (SCH 23390) and the dopamine D2 receptor antagonist sulpiride. Bupropion 27-36 dopamine receptor D2 Mus musculus 210-230 15363958-1 2004 This study demonstrated that bupropion hydrochloride, an effective antidepressant and a commonly used smoking cessation aid, dose-dependently caused clonic convulsions in mice, with the CD50 (convulsive dose50, i.e., the dose producing convulsions in 50% of mice) at 119.7 mg kg(-1). Bupropion 29-52 intercellular adhesion molecule 5, telencephalin Mus musculus 186-190 15363998-7 2004 It is concluded that the beta3-adrenoceptor subtype, as well as dopamine D2/D1 receptors, is responsible for the increase in oxygen consumption induced by bupropion. Bupropion 155-164 adrenoceptor beta 3 Rattus norvegicus 25-43 15602102-10 2004 The role of bupropion in SS is possibly related to its well-established specific inhibition of the cytochrome P450 2D6 pathway, increasing blood levels of SSRIs and tricyclic antidepressants. Bupropion 12-21 cytochrome P450 2D6 Homo sapiens 99-118 15335302-5 2004 Spontaneous reports of drug-induced urticaria to the Committee on Safety of Medicines, UK, over a 40-year period also implicate bupropion, selective serotonin re-uptake inhibitor antidepressants, angiotensin-converting enzyme inhibitors (ACEI), H2 and H1 antihistamines, and systemic antifungals. Bupropion 128-137 relaxin 2 Homo sapiens 245-254 15121764-9 2004 CYP2B6 could only be protected from the tTEPA-dependent inactivation by the 2B6-specific substrate bupropion but not by other substrates of CYP2B such as benzphetamine, testosterone, or 7-ethoxycoumarin. Bupropion 99-108 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 15322260-6 2004 The effects of bupropion and enantiomers of hydroxybupropion on human nAChR subtypes indicate that the (2S,3S) isomer is more potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) (functional IC(50) = 3.3 microM). Bupropion 15-24 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 70-75 15322260-6 2004 The effects of bupropion and enantiomers of hydroxybupropion on human nAChR subtypes indicate that the (2S,3S) isomer is more potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) (functional IC(50) = 3.3 microM). Bupropion 51-60 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 70-75 15322260-8 2004 Together, our results suggest that clinical and behavioral effects of bupropion arise from actions at nAChR as well as DA and NE transporters. Bupropion 70-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 102-107 15138759-5 2004 RESULTS: Carriers of the DRD2 A1 minor allele exhibited significant increases in the rewarding value of food following abstinence from smoking, and these effects were attenuated by bupropion treatment ( P=0.03 for medication by genotype interaction). Bupropion 181-190 dopamine receptor D2 Homo sapiens 25-29 15150377-0 2004 Bupropion for treatment of interferon-induced depression. Bupropion 0-9 interferon alpha 1 Homo sapiens 27-37 15150377-1 2004 OBJECTIVE: To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy. Bupropion 35-44 interferon alpha 1 Homo sapiens 63-73 15150377-1 2004 OBJECTIVE: To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy. Bupropion 35-44 interferon alpha 1 Homo sapiens 75-78 15150377-1 2004 OBJECTIVE: To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy. Bupropion 35-44 interferon alpha 1 Homo sapiens 190-193 15150377-2 2004 CASE SUMMARY: A 43-year-old white woman with chronic hepatitis C and severe IFN-induced depression was treated with sustained-release bupropion initiated at 150 mg/day for 7 days and 100 mg twice daily thereafter. Bupropion 134-143 interferon alpha 1 Homo sapiens 76-79 15150377-8 2004 CONCLUSIONS: Sustained-release bupropion might be of potential benefit in patients with interferon-induced depression. Bupropion 31-40 interferon alpha 1 Homo sapiens 88-98 15367832-1 2004 Bupropion is an increasingly prescribed agent to aid in smoking cessation. Bupropion 0-9 activation induced cytidine deaminase Homo sapiens 49-52 15155554-0 2004 Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Bupropion 41-50 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 15155554-2 2004 The goal of this work was to find a selective and potent chemical in vitro inhibitor toward CYP2B6 using bupropion hydroxylation as a model reaction. Bupropion 105-114 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 92-98 15787205-0 2004 [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]. Bupropion 68-77 solute carrier family 6 member 3 Homo sapiens 11-31 15787205-0 2004 [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]. Bupropion 68-77 solute carrier family 6 member 3 Homo sapiens 42-45 15787205-1 2004 Bupropion has an antidepressant effect through blocking the dopamine transporter. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 60-80 15787205-3 2004 After 3 weeks" bupropion treatment we studied the change in DAT activity, which corresponds to the occupancy of bupropion. Bupropion 112-121 solute carrier family 6 member 3 Homo sapiens 60-63 15787205-4 2004 The average occupancy of bupropion on DAT was similar to the international findings at 20.84% in 9 depressed patients. Bupropion 25-34 solute carrier family 6 member 3 Homo sapiens 38-41 15083067-0 2004 Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Bupropion 63-72 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-109 15083067-1 2004 Bupropion is primarily metabolized in human liver by cytochrome P450 (CYP) 2B6, an isoform that shows high interindividual variability in expression and catalysis. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-78 15083067-9 2004 In conclusion, the results of this study indicate that interindividual variability in bupropion hydroxylation is a consequence of interactions between environmental and genetic influences on CYP2B6 gene function. Bupropion 86-95 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 191-197 14977870-4 2004 CYP2B6 and CYP3A4 protein and activities were assessed by Western blotting, bupropion hydroxylation, and testosterone 6beta-hydroxylation, respectively. Bupropion 76-85 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 14977870-4 2004 CYP2B6 and CYP3A4 protein and activities were assessed by Western blotting, bupropion hydroxylation, and testosterone 6beta-hydroxylation, respectively. Bupropion 76-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 11-17 15082113-4 2004 Here we note that the safe, approved and commonly used psychiatric medicines bupropion (Wellbutrin), paroxetine (Paxil) and quetiapine (Seroquel) are respectively potent TNF, nitric oxide and histamine antagonists and thus might find some use in treatment of multiple myeloma. Bupropion 77-86 tumor necrosis factor Homo sapiens 170-173 15082113-4 2004 Here we note that the safe, approved and commonly used psychiatric medicines bupropion (Wellbutrin), paroxetine (Paxil) and quetiapine (Seroquel) are respectively potent TNF, nitric oxide and histamine antagonists and thus might find some use in treatment of multiple myeloma. Bupropion 88-98 tumor necrosis factor Homo sapiens 170-173 14668077-0 2003 Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Bupropion 66-89 dopamine receptor D2 Homo sapiens 9-13 14668077-5 2003 Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. Bupropion 11-20 dopamine receptor D2 Homo sapiens 186-190 14668077-7 2003 These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor. Bupropion 24-33 dopamine receptor D2 Homo sapiens 156-176 14515339-15 2003 Unlike D-fenfluramine, the D/L-fenfluramine-induced increase in PKC activity was partially resistant to PCPA pretreatment but was attenuated with bupropion, a dopamine transporter (DAT) inhibitor. Bupropion 146-155 solute carrier family 6 member 3 Rattus norvegicus 181-184 14550679-0 2003 In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Bupropion 20-29 solute carrier family 6 member 3 Homo sapiens 43-63 14550679-1 2003 BACKGROUND: Converging lines of evidence are consistent with an inhibitory effect of the antidepressant and smoking-cessation aid bupropion on dopamine and norepinephrine reuptake, but the in vivo effects of the drug at the human dopamine transporter (DAT) have not been studied to date. Bupropion 130-139 solute carrier family 6 member 3 Homo sapiens 230-250 14550679-1 2003 BACKGROUND: Converging lines of evidence are consistent with an inhibitory effect of the antidepressant and smoking-cessation aid bupropion on dopamine and norepinephrine reuptake, but the in vivo effects of the drug at the human dopamine transporter (DAT) have not been studied to date. Bupropion 130-139 solute carrier family 6 member 3 Homo sapiens 252-255 14550679-2 2003 This study employed positron emission tomography (PET) to assess the extent and duration of DAT receptor occupancy by bupropion and its metabolites under conditions of steady-state oral dosing with bupropion sustained-release (SR) in healthy volunteers. Bupropion 118-127 solute carrier family 6 member 3 Homo sapiens 92-95 14550679-2 2003 This study employed positron emission tomography (PET) to assess the extent and duration of DAT receptor occupancy by bupropion and its metabolites under conditions of steady-state oral dosing with bupropion sustained-release (SR) in healthy volunteers. Bupropion 198-207 solute carrier family 6 member 3 Homo sapiens 92-95 14550679-5 2003 RESULTS: Bupropion and its metabolites inhibited striatal uptake of the selective DAT-binding radioligand (11)C-betaCIT-FE in vivo. Bupropion 9-18 solute carrier family 6 member 3 Homo sapiens 82-85 14550679-6 2003 Three hours after the last dose of bupropion SR, average DAT occupancy by bupropion and its metabolites was 26%-a level that was maintained through the last PET assessment at 24 hours after dosing. Bupropion 35-44 solute carrier family 6 member 3 Homo sapiens 57-60 14550679-6 2003 Three hours after the last dose of bupropion SR, average DAT occupancy by bupropion and its metabolites was 26%-a level that was maintained through the last PET assessment at 24 hours after dosing. Bupropion 74-83 solute carrier family 6 member 3 Homo sapiens 57-60 14550679-7 2003 CONCLUSIONS: Bupropion and its metabolites induced a low occupancy of the striatal DAT over 24 hours under conditions of steady-state oral dosing with therapeutic doses of bupropion SR. Bupropion 13-22 solute carrier family 6 member 3 Homo sapiens 83-86 14550679-7 2003 CONCLUSIONS: Bupropion and its metabolites induced a low occupancy of the striatal DAT over 24 hours under conditions of steady-state oral dosing with therapeutic doses of bupropion SR. Bupropion 172-181 solute carrier family 6 member 3 Homo sapiens 83-86 12968991-0 2003 Chest pain during use of bupropion as an aid in smoking cessation. Bupropion 25-34 activation induced cytidine deaminase Homo sapiens 41-44 12968991-1 2003 AIMS: To investigate the cause of chest pain during the use of bupropion as an aid to stop smoking. Bupropion 63-72 activation induced cytidine deaminase Homo sapiens 79-82 12968991-2 2003 METHODS: The Netherlands Pharmacovigilance Centre received 22 reports of chest pain, associated with the use of bupropion as an aid to smoking cessation. Bupropion 112-121 activation induced cytidine deaminase Homo sapiens 128-131 14534519-0 2003 Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Bupropion 112-121 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 14-33 14534519-1 2003 AIM: Our objective was to study the effect of hormone replacement therapy and a combination oral contraceptive on the cytochrome P450 (CYP) 2B6 activity with bupropion (INN, amfebutamone) hydroxylation used as a probe reaction. Bupropion 158-167 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 118-143 14534519-10 2003 CONCLUSIONS: Hormone replacement therapy markedly inhibited the CYP2B6-catalyzed hydroxylation of bupropion, whereas a combination oral contraceptive had only a modest effect on CYP2B6 activity. Bupropion 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 64-70 14515060-0 2003 Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 86-92 14515060-2 2003 Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to be mediated by CYP2B6. Bupropion 79-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 25-44 14515060-2 2003 Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to be mediated by CYP2B6. Bupropion 79-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 46-52 14515060-2 2003 Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to be mediated by CYP2B6. Bupropion 79-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 153-159 14515060-3 2003 Bupropion may be a probe drug for CYP2B6 activity in humans. Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 34-40 14515060-8 2003 Population kinetic analysis revealed that bupropion total clearance via CYP2B6 alleles *1, *2, *5 and *6 did not differ, but clearance via allele *4 was 1.66-fold higher compared to wild-type allele *1 (P=0.001). Bupropion 42-51 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 72-78 14515060-9 2003 Corresponding to the high clearance of bupropion, carriers of the CYP2B6 genotype *1/*4 had significantly higher Cmax of hydroxybupropion compared to all other genotypes (P=0.03). Bupropion 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 66-72 14515060-10 2003 Only a minor fraction of the variability in bupropion and hydroxybupropion kinetics could be explained by the known CYP2B6 amino acid variants, in particular by the CYP2B6*4 allele. Bupropion 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 116-122 14515060-10 2003 Only a minor fraction of the variability in bupropion and hydroxybupropion kinetics could be explained by the known CYP2B6 amino acid variants, in particular by the CYP2B6*4 allele. Bupropion 44-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 165-171 14604466-2 2003 The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control. Bupropion 54-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 19-34 14604466-2 2003 The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control. Bupropion 54-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 36-39 14604466-2 2003 The possibility of cytochrome p450 (CYP) induction by bupropion (10 microM) was evaluated in-vitro by comparing catalytic activity, immunoreactive protein and CYP mRNA levels from human hepatocytes in primary culture versus cells treated with vehicle (0.5% methanol) and with rifampicin (rifampin) as a positive control. Bupropion 54-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 159-162 14604466-5 2003 However, 10 microM bupropion minimally altered CYP2B6 (1.4, 1.1, 0.8 fold). Bupropion 19-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 14604466-7 2003 Rifampicin (20 microM) increased CYP2E1 protein by 2.1 fold, while 10 microM bupropion minimally altered CYP2E1 protein (1.2 fold). Bupropion 77-86 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 105-111 12814665-1 2003 CYP2B6 metabolizes drugs such as nicotine and bupropion, and many toxins and carcinogens. Bupropion 46-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 12883127-0 2003 Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha? Bupropion 0-9 tumor necrosis factor Homo sapiens 56-83 12736634-1 2003 This work studies association between relapse during acute tryptophan depletion (ATD) and CSF level of tryptophan (TRP) in remitted depressives treated with sertraline or bupropion. Bupropion 171-180 colony stimulating factor 2 Homo sapiens 90-93 12598790-0 2003 Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. Bupropion 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 33-39 12474115-12 2002 CONCLUSIONS: These findings suggest that bupropion"s effect on REM latency and its AD action might be linked, possibly via dopamine (D(2)) receptor-mediated effects, or by noradrenergic mechanism(s). Bupropion 41-50 dopamine receptor D2 Homo sapiens 123-147 12518081-6 2002 The mechanisms by which bupropion acts as an aid in smoking cessation are unknown. Bupropion 24-33 activation induced cytidine deaminase Homo sapiens 45-48 12439223-2 2002 The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. Bupropion 39-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 12183670-1 2002 Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Bupropion 0-9 solute carrier family 6 member 3 Rattus norvegicus 121-124 12183670-10 2002 Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. Bupropion 6-15 solute carrier family 6 member 3 Rattus norvegicus 175-178 12183670-11 2002 The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent. Bupropion 64-73 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 19-24 12185406-0 2002 Bupropion occupancy of the dopamine transporter is low during clinical treatment. Bupropion 0-9 solute carrier family 6 member 3 Homo sapiens 27-47 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 11-20 solute carrier family 6 member 3 Homo sapiens 74-94 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 11-20 solute carrier family 6 member 3 Homo sapiens 96-99 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 11-20 solute carrier family 6 member 3 Homo sapiens 164-167 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 109-118 solute carrier family 6 member 3 Homo sapiens 74-94 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 109-118 solute carrier family 6 member 3 Homo sapiens 96-99 12185406-1 2002 RATIONALE: Bupropion is thought to treat major depression by blocking the dopamine transporter (DAT) because bupropion appears to have a selective affinity for the DAT. Bupropion 109-118 solute carrier family 6 member 3 Homo sapiens 164-167 12185406-2 2002 The validity of this mechanism has been questioned because the affinity of bupropion for the DAT is quite low. Bupropion 75-84 solute carrier family 6 member 3 Homo sapiens 93-96 12185406-3 2002 OBJECTIVE: To determine the occupancy of bupropion for the DAT during clinical treatment of patients with depression. Bupropion 41-50 solute carrier family 6 member 3 Homo sapiens 59-62 12185406-10 2002 CONCLUSIONS: Bupropion treatment occupies less than 22% of DAT sites. Bupropion 13-22 solute carrier family 6 member 3 Homo sapiens 59-62 12112414-5 2002 The DAT inhibitors cocaine, methylphenidate, and bupropion also increased c-Fos approximately 3-fold in hDAT cells. Bupropion 49-58 solute carrier family 6 member 3 Homo sapiens 4-7 12112414-5 2002 The DAT inhibitors cocaine, methylphenidate, and bupropion also increased c-Fos approximately 3-fold in hDAT cells. Bupropion 49-58 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 74-79 12070759-5 2002 We found that the substrate analogs bupropion, 3-bromomethcathinone, and 4-bromomethcathinone all inhibit uptake at the hNET with IC(50) values of 1370+/-140, 158+/-20, and 453+/-30 nM, respectively. Bupropion 36-45 solute carrier family 6 member 2 Homo sapiens 120-124 12021638-0 2002 Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion. Bupropion 101-110 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 16-22 12021638-1 2002 Some data indicate that bupropion inhibits the cytochrome P-450 enzyme CYP2D6, but very little published data is available on the extent of this inhibition. Bupropion 24-33 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 71-77 12021638-4 2002 His CYP2D6 phenotype was assessed using the test drug dextromethorphan before, during, and after treatment with bupropion. Bupropion 112-121 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 12021638-6 2002 Although the results from a single patient should be interpreted with great caution, the extent of the interaction indicates that bupropion might be a CYP2D6 inhibitor as potent as the most powerful CYP2D6 inhibitors known, such as quinidine and paroxetine. Bupropion 130-139 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 151-157 12021638-6 2002 Although the results from a single patient should be interpreted with great caution, the extent of the interaction indicates that bupropion might be a CYP2D6 inhibitor as potent as the most powerful CYP2D6 inhibitors known, such as quinidine and paroxetine. Bupropion 130-139 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 199-205 11744616-9 2002 The pharmacophores and the CYP2B6 model were used in conjunction to predict the K(m) values of substrates in a test set of five compounds and yielded satisfactory predictions for benzphetamine, cinnarizine, bupropion, and verapamil but not lidocaine. Bupropion 207-216 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-33 11445061-8 2001 Bupropion (a non-nicotine aid) also may be especially useful for patients with CVD. Bupropion 0-9 activation induced cytidine deaminase Homo sapiens 26-29 11454731-0 2001 Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Bupropion 80-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-53 11454731-1 2001 The purpose of this investigation was to evaluate the role of cytochrome P450 (CYP) 3A4 in human liver microsomal bupropion (BUP) hydroxylation. Bupropion 114-123 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-87 11454731-1 2001 The purpose of this investigation was to evaluate the role of cytochrome P450 (CYP) 3A4 in human liver microsomal bupropion (BUP) hydroxylation. Bupropion 125-128 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-87 11436960-1 2001 A 10-year-old boy with a history of heart transplantation had a potentially life-threatening decrease in his cyclosporine (CSA) blood levels during administration of bupropion. Bupropion 166-175 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 123-126 11436960-4 2001 The CSA-bupropion and CSA-methylphenidate interactions merit further investigation, particularly because psychotropic agents are often prescribed in combination with immunosuppressants in transplantation patients of all ages. Bupropion 8-17 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 4-7 11452710-11 2001 Mean values for area under the plasma concentration versus time curve (AUC0-->infinity), volume of distribution (Vd beta) normalized to body weight, maximum plasma concentration (Cmax), and elimination half-life (t1/2 beta) for bupropion were significantly (p < 0.05) greater in females than males, while clearance of bupropion normalized to body weight (CL/f) did not differ between males and females. Bupropion 231-240 interleukin 1 receptor like 1 Homo sapiens 216-225 11159797-0 2001 Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Bupropion 104-113 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 45-51 11159797-4 2001 The inhibition of bupropion hydroxylation in vitro by nelfinavir, ritonavir, and efavirenz indicates inhibitory potency versus CYP2B6 and suggests the potential for clinical drug interactions. Bupropion 18-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 127-133 11165307-0 2000 Elevated P-selectin on platelets in depression: response to bupropion. Bupropion 60-69 selectin P Homo sapiens 9-19 11165307-8 2000 After bupropion treatment, P-selectin remained high in depressed patients. Bupropion 6-15 selectin P Homo sapiens 27-37 10997936-0 2000 CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Bupropion 46-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 10997936-4 2000 In microsomes containing cDNA-expressed CYPs, hydroxybupropion formation was mediated only by CYP2B6 at 50 microM bupropion (K(m) 85 microM). Bupropion 53-62 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-100 10997936-5 2000 A CYP2B6 inhibitory antibody produced more than 95% inhibition of bupropion hydroxylation in four human livers. Bupropion 66-75 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 2-8 10997936-6 2000 Bupropion hydroxylation activity at 250 microM was highly correlated with S-mephenytoin N-demethylation activity (yielding nirvanol), another CYP2B6-mediated reaction, in a panel of 32 human livers (r = 0.94). Bupropion 0-9 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 142-148 10997936-7 2000 The CYP2B6 content of 12 human livers highly correlated with bupropion hydroxylation activity (r = 0.96). Bupropion 61-70 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 4-10 10997936-8 2000 Thus bupropion hydroxylation is mediated almost exclusively by CYP2B6 and can serve as an index reaction reflecting activity of this isoform. Bupropion 5-14 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 63-69 10997936-9 2000 IC(50) values for inhibition of a CYP2D6 index reaction (dextromethorphan O-demethylation) by bupropion and hydroxybupropion were 58 and 74 microM, respectively. Bupropion 94-103 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 34-40 10997944-0 2000 Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Bupropion 14-23 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 69-88 10997944-1 2000 The purpose of this study was to establish bupropion (BUP) hydroxylation as a selective in vitro marker of cytochrome P450 (CYP) 2B6 catalytic activity. Bupropion 43-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 107-132 10997944-1 2000 The purpose of this study was to establish bupropion (BUP) hydroxylation as a selective in vitro marker of cytochrome P450 (CYP) 2B6 catalytic activity. Bupropion 54-57 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 107-132 10997944-6 2000 Among a panel of cDNA-expressed P450 isoforms, CYP2B6 and CYP2E1 demonstrated the highest rates of BUP hydroxylation at 12 mM BUP (7.0 and 2.4 pmol/min/pmol of P450, respectively). Bupropion 99-102 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-36 10997944-6 2000 Among a panel of cDNA-expressed P450 isoforms, CYP2B6 and CYP2E1 demonstrated the highest rates of BUP hydroxylation at 12 mM BUP (7.0 and 2.4 pmol/min/pmol of P450, respectively). Bupropion 99-102 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 47-53 10997944-6 2000 Among a panel of cDNA-expressed P450 isoforms, CYP2B6 and CYP2E1 demonstrated the highest rates of BUP hydroxylation at 12 mM BUP (7.0 and 2.4 pmol/min/pmol of P450, respectively). Bupropion 99-102 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 58-64 10997944-6 2000 Among a panel of cDNA-expressed P450 isoforms, CYP2B6 and CYP2E1 demonstrated the highest rates of BUP hydroxylation at 12 mM BUP (7.0 and 2.4 pmol/min/pmol of P450, respectively). Bupropion 99-102 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 160-164 10773037-5 2000 Various DA transporter blockers (cocaine, methylphenidate, and bupropion) afforded complete protection against METH-induced decreases in DA uptake, without producing any effect themselves. Bupropion 63-72 solute carrier family 6 member 3 Homo sapiens 8-22